acitretin has been researched along with Palmoplantaris Pustulosis in 431 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 43 (9.98) | 18.7374 |
| 1990's | 57 (13.23) | 18.2507 |
| 2000's | 112 (25.99) | 29.6817 |
| 2010's | 161 (37.35) | 24.3611 |
| 2020's | 58 (13.46) | 2.80 |
| Authors | Studies |
|---|---|
| Chiewchanvit, S; Chuamanochan, M; Innu, T; Kiratikanon, S; Kwangsukstith, C; Netiviwat, J; Rujiwetpongstorn, R; Tosukhowong, T; Tovanabutra, N; Wonglamsam, P | 1 |
| Aung, PP; Cho, WC; Curry, JL; Gill, P; Heberton, M; Murphy, MB; Nagarajan, P; Nikolaou, V; Om, A; Patel, AB; Ruiz-Bañobre, J; Seervai, RNH; Torres-Cabala, CA; Yamamoto, T | 1 |
| Xu, Q; Yang, Y; Yao, Z; Zhang, Z | 1 |
| Amici, JM; Bergqvist, C; Beylot-Barry, M; Corgibet, F; Ly, S; Sbidian, E; Seï, JF; Seneschal, J | 1 |
| Capalbo, E; Cartocci, A; Cinotti, E; Cortonesi, G; Orsini, C; Rubegni, P; Trovato, E | 1 |
| Ariane, M; Mahé, E | 1 |
| Bahloul, E; Bougacha-Elleuch, N; Ennouri, M; Fakhfakh, F; Marrakchi, S; Sellami, K; Turki, H | 1 |
| Asili, P; Daneshpajooh, M; Mirahmad, M; Nasimi, M; Sedaghatzadeh, M; Tootoonchi, N | 1 |
| Chen, M; Dong, Z; Du, Y; Wang, F; Yan, Q | 1 |
| Haiyan, H; Lingling, LI; Xiaoran, Z; Xun, LI; Yi, L; Zi, W | 1 |
| Katharina, M; Martin, L; Matthias, B; Sylvia, S; Ulrich, M | 1 |
| Geng, A; Jia, B; Pei, T; Zhao, X | 1 |
| Crasto, D; Karai, L; Sherkin, S; Skopit, S; Summa, C; Whitney, Z | 1 |
| Hsieh, CY; Tsai, TF | 1 |
| Chen, Y; Liu, Y; Miao, C; Wang, Z; Xiang, X; Xu, Z | 1 |
| Aubert, H; Balguerie, X; Barbarot, S; Barthélémy, H; Beauchet, A; Boralevi, F; Di Lernia, V; Girard, C; Hadj-Rabia, S; Mahé, E; Mallet, S; Martin, L; Mazereeuw-Hautier, J; Phan, A; Phan, C; Piram, M; Severino-Freire, M; Zitouni, J | 1 |
| Chen, W; He, Y; Kuang, Y; Zhou, X; Zhu, W | 1 |
| Chen, Y; Li, W; Liu, Y; Ma, L; Miao, C; Qi, Z; Wang, Z; Xiang, X; Xu, Z; Zhang, Y; Zhang, Z; Zhao, X | 1 |
| Carrascosa, JM | 1 |
| Alabas, OA; Bewley, A; Griffiths, CEM; Hampton, PJ; Laws, PM; Lunt, M; Mason, KJ; Owen, CM; Reynolds, NJ; Smith, CH; Warren, RB; Yiu, ZZN | 1 |
| Aksan, B; Arica, DA; Arıca, İE; Aydemir, B; Baykal Selcuk, LB; Dere, G; Etgu, F; Gündogdu, M; Kulakli, S; Oguz, ID; Oguzer, SE; Onder, S; Saral, Y; Yayli, S | 1 |
| Chang, YL; Chen, YJ; Ho, HJ; Kuo, CM; Lin, TL; Wu, CY | 1 |
| Jin, HZ; Wang, HM; Xu, JM | 1 |
| Dev, PP; Verma, P | 1 |
| Chang, YC; Chen, CB; Chen, WT; Chung, WH; Hui, RC; Wang, CW; Wang, CY | 1 |
| Jiang, WW; Wang, XY; Wang, YM; Zhang, CL; Zhang, Q; Zhu, SM | 1 |
| Bulut, H; Engin, B; Gökalp, E; Kutlubay, Z; Özkoca, D; Serdaroğlu, S; Songür, A; Tanakol, A; Tüzün, Y; Vehid, HE | 1 |
| Gabriel, A; Gogler-Piglowska, A; Kupczak, M; Michalski, M; Mielanczyk, A; Mielanczyk, Ł; Mrowiec, K; Neugebauer, D; Scieglinska, D; Skonieczna, M | 1 |
| Guo, J; He, F; Long, F; Tu, J; Yin, Z | 1 |
| Montanez-Wiscovich, ME; Shivers, L | 1 |
| Chen, GH; Chen, JS; Fu, Z; Luo, XY; Ren, FL; Tan, Q; Wang, H; Yang, H | 1 |
| Silverberg, JI; Singh, P | 1 |
| Bahtaoui, W; Chiheb, S; El Fetoiki, FZ; Hali, F | 1 |
| Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Prater, EF; Rahimi, RS; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Tapper, EB; Wong, EB; Wu, JJ | 1 |
| Ding, Y; Li, Y; Shi, Y; Yu, N | 1 |
| Cave, A; Kinsler, VA; Martinez, AE; Mellerio, JE; Plumptre, I | 1 |
| Bonifati, C; Graceffa, D; Morrone, A; Pacifico, A | 1 |
| Hao, PS; Hu, X; Li, M | 1 |
| Bagle, T; Dabherao, S; Joshi, P; Vishwanath, T; Viswanath, V | 1 |
| Aichelburg, MC; Holzer, G; Pinkowicz, A; Radakovic, S; Sator, PG; Tanew, A | 1 |
| Brenaut, É | 1 |
| Villani, AP | 1 |
| Annunziata, MC; Apalla, Z; Carrera, C; Fabbrocini, G; Fattore, D; Giacchero, D; Lallas, A; Lallas, K; Lazaridou, E; Nikolaou, V; Ortiz-Brugués, A; Patri, A; Peris, K; Riganti, J; Rigopoulos, D; Romano, MC; Rossi, E; Sibaud, V; Sollena, P; Stratigos, AJ; Voudouri, D | 1 |
| Chavan, D; Jamale, V; Kale, M; Nikam, B; Shah, S | 1 |
| Babuna Kobaner, G; Bölük, KN; Polat Ekinci, A | 1 |
| Aslan Kayıran, M; Aytekin, S; Kara Polat, A; Karadag, AS; Kıvanc Altunay, I; Koku Aksu, AE; Oguz Topal, I; Ozkok Akbulut, T; Ozkur, E; Topaloglu Demir, F | 1 |
| Albela, H; Begum, S; Leong, KF | 1 |
| Ahn, KJ; Cho, YA; Choe, YB; Hong, JR; Hong, JY; Jeong, H; Kim, H; Kim, SM; Lee, YW; Yang, HS | 1 |
| Chat, VS; Han, G; Kearns, DG; Uppal, SK; Wu, JJ | 1 |
| Chen, L; Ju, X; Li, J; Wang, S; Yao, Y; Zhang, B; Zheng, S | 1 |
| Barker, JN; Mahil, SK; Raharja, A | 1 |
| Chen, F; Chen, W; Ding, Y; Gao, Y; Liu, N; Yu, N; Zheng, J | 1 |
| Chanprapaph, K; Iamsumang, W; Pinyowiwat, P; Rattanakaemakorn, P; Suchonwanit, P | 1 |
| Aylı, M; Caliskan, E; Coban, SN; Esme, P; Ugur, B | 1 |
| Bergman, P; Ehrström, M; Eidsmo, L; Lysell, J; Padhi, A; Ramesh, A; Simon, M; Sonkoly, E; Srivastava, A | 1 |
| Beatty, P; Byrne, N; Connolly, M; Killion, L; Mahon, JM; Salim, A; Tobin, AM | 1 |
| Croney, S | 1 |
| Fan, X; Li, Z; Liu, X; Wang, G; Yu, C | 1 |
| An, J; Gao, X; Li, J; Li, R; Teng, X; Wang, X; Wu, J; Xia, L; Xia, Y; Zhang, D | 1 |
| Frambach, Y; Gerdes, S; Jacobi, A; Mössner, R; Philipp, S; Schill, T; Steinz, K; Weyergraf, A; Wilsmann-Theis, D | 1 |
| Armstrong, AW; Prussick, R; Siegel, MP; Van Voorhees, AS; Wu, JJ | 1 |
| Addis, A; Adenubiova, E; Busard, CI; Cazzaniga, S; Cohen, AD; Feldhamer, I; Gkalpakiotis, S; Hutten, BA; Kojanova, M; Lichem, R; Naldi, L; Quehenberger, F; Spuls, PI; Stern, RS; Wolf, P | 1 |
| Schmutz, JL | 1 |
| Badavanis, G; Monastirli, A; Pasmatzi, E; Tsambaos, D | 1 |
| Gao, Q; Liu, JH; Luo, DQ; Wang, F; Wu, HH; Zhao, YK | 1 |
| Chen, Z; Shi, Y; Subedi, S; Yu, Q | 1 |
| Chen, H; Chen, P; Li, C; Liang, J; Tian, X; Xue, R; Zeng, K; Zhang, X | 1 |
| Jakhar, D; Jha, AK; Sonthalia, S | 1 |
| Armstrong, AW; Enos, CW; Gottlieb, A; Langley, RG; Lebwohl, M; Merola, JF; Ryan, C; Siegel, MP; Van Voorhees, AS; Weinberg, JM; Whitlock, SM; Wu, JJ | 1 |
| Abd El-Gawad, AEH; Abo El-Magd, NF; Abu Hashim, II; El-Sheakh, AR; Hamed, MF | 1 |
| Antiga, E; Bergonzi, MC; Bilia, AR; Caproni, M; Isacchi, B | 1 |
| Jin, H; Li, F; Shu, D; Wu, C; Zhu, T | 1 |
| Koh, WL; Oon, HH; Tan, WP | 1 |
| Bao, F; Shang, P; Sun, L; Wang, Q; Wu, M; Yu, C; Zhang, F; Zhou, G | 1 |
| Chen, W; Chen, X; Wu, L; Zhu, W | 1 |
| Fernández, J; Sánchez, M; Valenzuela, F; Zamudio, A | 1 |
| Dogra, S; Handa, S; Kumar, S; Narang, T | 1 |
| Dommasch, ED; Gagne, JJ; Garry, EM; Joyce, CJ; Lee, MP | 1 |
| Curry, ZA; Feldman, SR; Heath, MS; Sahni, DR | 1 |
| Chen, W; Chen, X; Peng, C; Zhang, W; Zhang, X; Zhu, W | 1 |
| Barygina, V; Becatti, M; Fiorillo, C; Lotti, T; Taddei, N | 1 |
| Abalde, T; Álvarez-López, J; Batalla, A; Cabanillas, M; Fernández-Díaz, L; Fernández-Torres, R; Flórez, Á; Fonseca, E; León, Á; Monteagudo, B; Pardavila-Riveiro, R; Rodríguez-Lojo, R; Rodríguez-Pazos, L; Salgado-Boquete, L; Seoane-Pose, MJ; Suárez-Conde, I; Valdés, F; Vázquez-Veiga, H; Zulaica, Á | 1 |
| Bewley, AP; Calzavara-Pinton, PG; Hansen, JB; Nyeland, ME; Shear, NH; Signorovitch, J | 1 |
| Chularojanamontri, L; Limphoka, P; Silpa-Archa, N; Wongpraparut, C | 1 |
| Ashcroft, DM; Griffiths, CEM; Jabbar-Lopez, ZK; Kleyn, CE; Mason, KJ; McElhone, K; Owen, CM; Reynolds, NJ; Smith, CH; Warren, RB; Williams, S; Wilson, N; Yiu, ZZN | 1 |
| Abdollahimajd, F; Baradaran-Rafii, A; Ghalamkarpour, F; Rudolph, RI; Sadoughi, MM; Younespour, S; Zargari, O | 1 |
| Baran, R; Chiheb, S; Daniel, CR; Di Chiacchio, N; Gregoriou, S; Grover, C; Haneke, E; Iorizzo, M; Pasch, M; Piraccini, BM; Rich, P; Richert, B; Rigopoulos, D; Rompoti, N; Rubin, AI; Singal, A; Starace, M; Tosti, A; Triantafyllopoulou, I; Zaiac, M | 1 |
| Girolomoni, G; Gisondi, P; Mattiucci, A; Tonin, B | 1 |
| Cho, S; Lee, H | 1 |
| Bo, KP; Gao, Q; Ma, AL; Ma, W; Shi, HJ; Song, HB; Wang, L; Zhang, N; Zhou, H | 1 |
| Carrascosa, JM; Daudén, E; Guisado, C; Puig, L; Sulleiro, S | 1 |
| Baran, A; Flisiak, I; Kiluk, P; Maciaszek, M; Świderska, M | 1 |
| Arnone, M; Bernardo, WM; Carvalho, AVE; Takahashí, MDF | 1 |
| Duan, Y; Guo, D; Guo, W; Jin, W; Mao, J; Wu, M; Xu, N; Zhang, Y; Zhou, J; Zou, J | 1 |
| Li, C; Li, M; Liang, J; Ni, C; Yao, Z; Yu, H; Zhang, Z | 1 |
| Baran, A; Flisiak, I; Kiluk, P; Maciaszek, M; Myśliwiec, H; Świderska, M | 1 |
| Bronze-da-Rocha, E; Custódio, JB; Fernandes, JC; Figueiredo, A; Moreiras, A; Oliveira, H; Rocha-Pereira, P; Santos-Silva, A; Silva, FS | 1 |
| Höpfl, R; Huemer, HP; Martini, K; Müller, H | 1 |
| Ahern, T; Kirby, B; O'Shea, D; Reid, CT; Tobin, AM | 1 |
| Davis, SA; Feldman, SR; Yentzer, BA | 1 |
| Belinchón, I; Carrascosa, JM; Carretero, G; Dehesa, L; Ferrandiz, C; González-Quesada, A; Jorquera, E; Moreno, JC; Muñoz, C; Notario, J; Peral, F; Puig, L; Ribera, M; Vanaclocha, F; Vidal, D | 1 |
| Andres, C; Brockow, K; Gutermuth, J; Mourantchanian, V; Radopoulou, E; Ring, J; Zirbs, M | 1 |
| Aktürk, AS; Bayramgurler, D; Bilen, N; Cağlayan, C; Demirsoy, EO; Kıran, R; Salman, S | 1 |
| Antunes, J; Filipe, P; Marques, MS; Pacheco, D; Silva, R; Travassos, AR | 1 |
| Alsina, M; Belinchón, I; Carrascosa, JM; Carretero, G; de la Cueva, P; Ferrándiz, C; Fonseca, E; García-Bustínduy, M; García-Patos, V; Herrera, E; Lafuente-Urrez, RF; López-Estebaranz, JL; Marrón, SE; Moreno, JC; Notario, J; Puig, L; Ribera, M; Rivera, R; Rodriguez-Cerdeira, C; Romero, A; Ruiz-Villaverde, R; Sánchez-Regaña, M; Taberner, R; Vidal, D | 1 |
| Balahoroglu, R; Bilgili, SG; Calka, O; Celik, HT; Ertugrul, DT; Kalkan, G; Karadag, AS; Takci, Z | 1 |
| de Muret, A; Khashoggi, M; Machet, L; Samimi, M | 1 |
| Fernandez, MP; Fisher, V; Krejci-Manwaring, J | 1 |
| Bagel, J; Blauvelt, A; Hsu, S; Hugh, J; Lebwohl, M; Nijhawan, RI; Van Voorhees, AS; Weinberg, JM | 1 |
| Burden, AD; Burfield, L | 1 |
| Gaddoni, G; Odorici, G; Patrizi, A; Savoia, F; Tengattini, V | 1 |
| Dogra, S; Yadav, S | 1 |
| Alsina-Gibert, M; Belinchón, I; Carazo, C; Carrascosa, JM; Carretero, G; Dauden, E; De la Cueva-Dobao, P; Ferrán, M; Ferrandiz, C; García-Doval, I; Gómez-García, FJ; Herrera-Ceballos, E; Jiménez-Puya, R; López-Estebaranz, JL; Rivera, R; Sánchez-Carazo, JL; Torrado, R; Vanaclocha Sebastián, F | 1 |
| Armour, K; Chan, BC; George, PM; Maurice, PD; Reid, N; Scott, RS | 1 |
| Chu, GY; Hu, SC; Lan, CC | 1 |
| Chiarolanza, I; Di Lernia, V; Ficarelli, E; Lallas, A; Possemato, N; Salvarani, C | 1 |
| Bertoldi, AM; Borghi, A; Caroppo, F; Corazza, M; Virgili, A | 1 |
| Aractingi, S; Aubin, F; Barnetche, T; Beylot-Barry, M; Cantagrel, A; Joly, P; Jullien, D; Le Maitre, M; Misery, L; Ortonne, JP; Paul, C; Richard, MA; Rouzaud, M; Sevrain, M; Villani, AP | 1 |
| Dai, YJ; Li, YY; Liang, XA; Pan, QH; Xie, ZJ; Xing, YX; Zeng, HM; Zheng, ZA | 1 |
| Akçali, C; Guven, EH; Guvenc, U; Inaloz, HS; Kirtak, N; Ozgoztasi, O | 1 |
| Errichetti, E; Patrone, P; Pegolo, E; Stinco, G | 1 |
| Akdeniz, N; Karadag, AS; Ozlu, E; Uzuncakmak, TK | 1 |
| Lu, C; May, B; Parker, S; Xue, CC; Yu, JJ; Zhang, AL; Zhang, CS | 1 |
| Brod, BA; Callis Duffin, K; Gelfand, JM; Kalb, RE; Krueger, GG; Linn, KA; Robertson, AD; Schleicher, SM; Shin, DB; Shinohara, RT; Sperber, BR; Stierstorfer, MB; Takeshita, J; Troxel, AB; Van Voorhees, AS; Wang, S; Weisman, JD | 1 |
| Akbulak, O; Akdeniz, N; Bilgili, SG; Karadag, AS; Ozkanli, S; Zemheri, E; Zenginkinet, T; Zindanci, I | 1 |
| Kirby, B; Ryan, C | 1 |
| Foley, P; Kelly, JB; Strober, BE | 1 |
| Foulkes, AC; Warren, RB | 1 |
| Abeni, D; Giannantoni, P; Paradisi, A; Tabolli, S | 1 |
| Ara, M; Gracia, T; Pastushenko, E | 1 |
| Al-Ismail, D; Anderson, E; Batul Syed, S; Burden-Teh, E; Carmichael, A; Caruana, D; Darne, S; Dolman, S; Glover, M; Helbling, I; Hughes, B; Hughes, J; Jones, V; Jury, C; Kalavala, M; Katugampola, R; Lam, ML; McPherson, T; Moore, A; Murphy, R; Natarajan, S; Richards, L; Taibjee, SM; Taylor, A; Webster, S | 1 |
| Frambach, Y; Gerdes, S; Jacobi, A; Mössner, R; Philipp, S; Weyergraf, AJ; Wilsmann-Theis, D | 1 |
| He, CX; He, YB; Jin, HZ; Li, F; Liu, TJ; Qiao, J; Shu, D; Wu, C; Yu, XL; Zhang, Y | 1 |
| Biterman, H; Cohen, AD; Feldhamer, I; Freud, T; Greenberg-Dotan, S; Harman-Boehm, I; Moser, H; Polishchuk, I; Shalom, G; Zisman, D | 1 |
| García-Arpa, M; López-Nieto, M; Sánchez-Caminero, MP; Santiago Sánchez-Mateos, JL | 1 |
| Bangsgaard, N; Rørbye, C; Skov, L | 1 |
| Chen, M; Chen, W; Chen, X; He, Y; Li, J; Su, J; Zhang, W; Zhao, Y; Zhu, W | 1 |
| Armstrong, AW; Blauvelt, A; Krueger, GG | 1 |
| Au, SC; Garber, C; Gottlieb, A; Plotnikova, N; Sorensen, EP | 1 |
| Albayrak, H; Albayrak, S; Erfan, G; Gelincik, I; Kulac, M; Tasolar, K; Yanik, ME | 1 |
| Maverakis, E; Patel, F; Sharma, A; Wilken, R | 1 |
| Arenberger, P; Bachelez, H; Barker, J; Dauden, E; de Jong, EM; Feist, E; Gisondi, P; Jacobs, A; Jobling, R; Kemény, L; Maccarone, M; Mrowietz, U; Nast, A; Ormerod, AD; Papp, KA; Paul, C; Reich, K; Rosumeck, S; Saiag, P; Smith, C; Spuls, PI; Talme, T; Thio, HB; van de Kerkhof, P; Werner, RN; Yawalkar, N | 1 |
| Bae, SH; Kim, SJ; Lee, JB; Lee, SC; Won, YH; Yun, SJ | 1 |
| Abasq, C; Aubin, F; Barbarot, S; Begon, E; Boralevi, F; Bourrat, E; Bursztejn, AC; Charbit, L; Chiaverini, C; Droitcourt, C; Hadj-Rabia, S; Lasek, A; Mahé, E; Mallet, S; Maruani, A; Mazereeuw-Hautier, J; Phan, A; Plantin, P; Souillet, AL | 1 |
| Aldredge, L; Armstrong, AW; Yamauchi, PS | 1 |
| Carpentieri, A; De Marco, IM; Loconsole, F; Loiacono, A; Pacello, L; Picconi, O | 1 |
| Lim, HW; Mehta, D | 1 |
| Guo, X; Lu, C; May, BH; Xue, CC; Yang, L; Yu, JJ; Zhang, AL; Zhang, CS | 1 |
| Cheung, L; Weinstein, M | 1 |
| Ben Salem, C; Fathallah, N; Ghariani, N; Hmouda, H; Larif, S; Slim, R | 1 |
| Alfageme Roldán, F; Bermejo Hernando, A; Calvo González, JL; Marqués Sánchez, P | 1 |
| Arakawa, A; Prinz, JC; Ruzicka, T | 1 |
| Raposo, I; Torres, T | 1 |
| Ghoreschi, K; Volc, S | 1 |
| Anliker, M; Boehncke, WH; Borradori, L; Conrad, C; French, LE; Gilliet, M; Häusermann, P; Itin, P; Kolios, AG; Laffitte, E; Mainetti, C; Navarini, AA; Yawalkar, N | 1 |
| Markham, T; O'Gorman, SM; Storan, ER | 1 |
| Divya, G; Gupta, S; Jayakumar, R; Panonnummal, R; Sabitha, M | 1 |
| Belloni Fortina, A; Bonamonte, D; Cambiaghi, S; Corazza, M; Di Lernia, V; Di Nuzzo, S; Gisondi, P; Guarneri, C; Lasagni, C; Neri, I; Panzone, M | 1 |
| Choe, YB; Choi, JH; Kim, KJ; Kim, NI; Kim, TY; Lee, JH; Park, CJ; Song, HJ; Yoo, HJ; Youn, JI | 1 |
| Leonardi, CL | 1 |
| Chen, X; Kuang, Y; Li, J; Liu, P; Su, J; Zhang, J; Zhu, W | 1 |
| Alpsoy, E; Bulbul-Baskan, E; Ergun, T; Onsun, N; Salman, A; Saricam, MH; Sarioz, A; Seckin Gencosmanoglu, D | 1 |
| Benoit, S; Hamm, H; Haug, V; Wohlleben, M | 1 |
| Chiricozzi, A; Dini, V; Gualtieri, B; Panduri, S; Romanelli, M; Tonini, A | 1 |
| Berman, E; Cohen, AD; Eran, CB; Feldhamer, I; Freud, T; Hodak, E; Oren, S; Pavlovsky, L; Shalom, G; Ziv, M | 1 |
| Cline, A; Feldman, SR; Smith, J | 1 |
| Cheng, R; Guo, Y; Huang, P; Li, M; Liang, J; Lu, Z; Wang, Y; Yan, M; Yao, Z | 1 |
| Kim, BS; Kim, GW; Kim, HS; Kim, JM; Kim, MB; Ko, HC; Lee, WK | 1 |
| Bo, KP; Chen, WG; Ma, W; Shi, HJ; Song, HB; Xia, L; Yang, J; Zhou, H | 1 |
| Arenberger, P; Cetkovska, P; Dolezal, T; Fialova, J; Gkalpakiotis, S; Jircikova, J; Kojanova, M | 1 |
| Barker, JN; Capon, F; Choon, SE; Lau, BW; Lim, DZ | 1 |
| Li, Y; Wu, X | 1 |
| Mahé, E | 1 |
| Christopher, GF; Meires, J | 1 |
| Ergin, S; Ersoy-Evans, S; Ozkaya, O; Sahin, S | 1 |
| Balkrishnan, R; Boles, A; Camacho, FT; Clark, A; Feldman, SR; Fleischer, AB; Makhzoumi, Z; Pearce, DJ; Yelverton, CB; Yentzer, BA | 1 |
| Koo, J; Murase, JE; Pang, ML | 1 |
| Huh, W; Kim, DW; Kim, HG; Kim, HK; Kim, JW; Kim, MH; Kim, YG; Lee, JH; Lee, SY; Park, HD; Youn, JI | 1 |
| Antiga, E; Caproni, M; Del Bianco, E; Fabbri, P; Melani, L; Volpi, W | 1 |
| Balkrishnan, R; Boles, A; Camacho, FT; Clark, A; Feldman, SR; Fleischer, AB; Pearce, DJ; Yelverton, CB; Yentzer, BA | 1 |
| Altieri, E; Baricordi, O; Borghi, A; Fogli, E; Melchiorri, L; Rizzo, R; Stignani, M; Virgili, A | 1 |
| Gibney, J; Hughes, R; Kirby, B | 1 |
| Baysal, I; Engin, B; Mevlitoğlu, I; Ozdemir, M | 1 |
| Colsman, A; Renner, R; Sticherling, M | 1 |
| Leithead, JA; MacGilchrist, AJ; Simpson, KJ | 1 |
| Cameli, N; Piraccini, BM; Ricotti, C; Romanelli, P; Tosti, A | 1 |
| Abdalmoati, A; Al-Makhzangy, I; Attwa, E; Nassar, A; Nofal, A | 1 |
| Trobisch, P; Wuenschel, M | 1 |
| Dogra, S; Kaur, I; Malhotra, S; Mittal, R; Pandhi, P | 1 |
| Bai, YP; Song, PH; Yang, DQ; You, LP; Zhang, LX | 1 |
| Grabbe, J; Merl, V; Rose, C; Shimanovich, I; Zillikens, D | 1 |
| Aegerter, P; Beauchet, A; Mahé, E; Saiag, P | 1 |
| Jordá Cuevas, E; Jordá, E; López Castillo, V; López, V; Martí Fajardo, N; Martí, N; Martin Hernández, JM; Martín, JM; Molina Gallardo, I; Molina, I | 1 |
| Balevi, A; Mevlitoğlu, I; Ozdemir, M | 1 |
| Antoniou, C; Katsambas, A; Moustou, AE; Nicolaidou, E; Stratigos, A | 1 |
| Seckin, D; Yildiz, A | 1 |
| Baldo, A; Monfrecola, G | 1 |
| Barbo, ML; Jaime, TJ; Rodrigues, BA; Simis, DR | 1 |
| Choi, JS; Chun, JM; Han, JY; Kim, CH; Koren, G; Lee, SY; Nava-Ocampo, AA; Park, HD; Park, Q | 1 |
| Cottone, M; Mocciaro, F; Orlando, A; Renna, S | 1 |
| Lee, CS; Li, K | 1 |
| Alomar, A; Barco, D; Puig, L; Vilarrasa, E | 1 |
| Chandran, NS; Chong, WS | 1 |
| Campalani, E; Goodfield, MJ; Ormerod, AD | 1 |
| Bessis, D; Girard, C; Guillot, B; Kluger, N | 1 |
| Booij, MT; Van De Kerkhof, PC | 1 |
| Agrawal, Y; Petkar, KC; Sawant, KK | 1 |
| Di Lernia, V | 1 |
| O'Rielly, DD; Rahman, P | 1 |
| Belinchón, I; Carrascosa, JM; Carretero, G; Daudén, E; Ferrándiz, C; López-Estebaranz, JL; Puig, L; Sánchez-Regaña, M; Vidal, D | 1 |
| Lotti, T; Pescitelli, L; Prignano, F; Ricceri, F; Ruffo, G | 1 |
| Bagel, J; Feldman, SR; Halvorson, CR; Lapolla, W; Yentzer, BA | 1 |
| Hayes, J; Koo, J | 1 |
| Busse, K; Koo, J | 1 |
| Rallis, E; Verros, CD | 1 |
| Aguayo, R; Baradad, M; Casanova, JM; Sanmartín, V | 1 |
| Chiu, MW; Hillman, JD; Monroe, HR | 1 |
| Boulinguez, S | 1 |
| Foulkes, AC; Griffiths, CE; Grindlay, DJ; Warren, RB | 1 |
| Dunn, LK; Feldman, SR; Gaar, LR; O'Neill, JL; Yentzer, BA | 1 |
| Cerri, A; Colombo, L; Crespi, E; Gualandri, L; Mapelli, ET; Marconi, M; Menni, S | 1 |
| Dabade, TS; Feldman, SR; Haushalter, K; Murad, EJ; Pearce, DJ; Rowell, R | 1 |
| Arrue, I; Carnero, L; González-Pérez, R; Soloeta, R | 1 |
| Dabade, TS; Feldman, SR; Ghasri, P; Yentzer, BA | 1 |
| Gu, W; Shi, F; Zhao, G | 1 |
| Dubertret, L | 1 |
| Debbiche, AC; Khaddar, RK; Mahjoub, WK; Mokni, M; Osman, AB; Sassi, MB; Zaraa, I | 1 |
| Arcese, A; Camplone, G; Carlesimo, M; Di Russo, PP; Gamba, A; La Pietra, M; Mari, E; Orsini, D | 1 |
| Lipsker, D; Lutz, V | 1 |
| Anstey, AV; Ingram, JR; Piguet, V | 1 |
| Cassano, N; Vena, GA | 1 |
| Antiga, E; Caproni, M; Cardilicchia, E; Fabbri, P; Filì, L; Maggi, L; Manuelli, C; Parronchi, P; Volpi, W | 1 |
| Oakley, A; Simpkin, S | 1 |
| Dogra, S; Jain, A; Kanwar, AJ | 1 |
| Daudén, E; Gallo, E; García-Diez, A; Llamas-Velasco, M | 1 |
| Bebo, BF; Brod, BA; Callis Duffin, K; Gelfand, JM; Kalb, RE; Krueger, GG; Schleicher, SM; Shin, DB; Sperber, BR; Troxel, AB; Van Voorhees, AS; Wan, J; Weisman, JD; Yeung, H | 1 |
| Cao, W; Feng, J; Li, X; Ma, H; Niu, X; Zhang, X | 1 |
| Frambach, Y; Gerdes, S; Mössner, R; Philipp, S; Rotterdam, S; Weyergraf, A; Wilsmann-Theis, D | 1 |
| Handa, S; Janagond, AB; Kanwar, AJ | 1 |
| Bettoli, V; Virgili, A; Zauli, S | 1 |
| Anwar, MI; Hasnain, SH; Iftikhar, N; Ishaq, BM | 1 |
| Bovenschen, HJ; Zweegers, J | 1 |
| Pelivani, N; Schibler, F; Spanou, Z; Tang, H; Tang, MM; Yawalkar, N | 1 |
| Cuhadaroglu, C; Erelel, M; Kiliçaslan, Z; Kiyan, E; Korular, D | 1 |
| Gordon, KB; McClure, SL; Valentine, J | 1 |
| Bournerias, I; Frau, E; Labetoulle, M; Offret, H | 1 |
| van de Kerkhof, P | 1 |
| David-Bajar, K; Elston, DM; Kobayashi, TT; Libow, LF | 1 |
| Agnew, KL; Bunker, CB | 1 |
| Callis, KP; Carlin, CS; Krueger, GG | 1 |
| Chave, TA; Hutchinson, PE; Mortimer, NJ | 1 |
| Choe, YB; Park, JY; Rim, JH; Youn, JI | 1 |
| Bryan, ME; Johnson, SM; Lienhart, K; Smoller, BR | 1 |
| Kormeili, T; Lowe, NJ; Patnaik, R; Rizk, D; Yamauchi, PS | 1 |
| Zanolli, M | 1 |
| Carrasco, D; Lebwohl, M; Tannis, C | 1 |
| Lebwohl, M; Maryles, S; Rozenblit, M | 1 |
| Lebwohl, M; Rozenblit, M; Spuls, PI | 1 |
| Feldman, S; Koo, J; Lebwohl, M; Menter, A | 1 |
| Egan, CA; Florell, SR; Krueger, GG | 1 |
| Dubin, DB; Ellis, R; Tanner, W | 1 |
| Combemale, P; Dupin, M; Estival, JL; Kanitakis, J | 1 |
| Koo, J; Lee, E | 2 |
| Feldman, SR; Koo, J; Lebwohl, M; Menter, A | 1 |
| Borroni, G; Brazzelli, V; Martinoli, S; Prestinari, F | 1 |
| Lois, N; White, M | 1 |
| Karlhofer, F; Kopp, T; Schneeberger, A; Stingl, G; Szépfalusi, Z; Tanew, A | 1 |
| Short, MW; Vaughan, TK | 1 |
| Feldman, SR; Margolis, DJ; Nijsten, T; Rolstad, T | 1 |
| Feldman, SR; Margolis, DJ; Nijsten, T; Rolstad, T; Stern, RS | 1 |
| Amichai, B; Grunwald, MH; Shiri, J | 1 |
| Evans, C; Feldman, SR; Russell, MW | 1 |
| Cather, JC; Menter, A | 1 |
| Koo, J; Lee, CS | 1 |
| Angioni, R; Beck-Peccoz, P; Cattaneo, A; Corbetta, S; Spada, A | 1 |
| Barker, JN; Brenchley, PE; Campalani, E; Detmar, MJ; Fairhurst, DA; Griffiths, CE; Plant, DJ; Read, IR; Smith, CH; Summers, AM; Young, HS | 1 |
| Allen, MH; Barker, JN; Burden, AD; Campalani, E; Crook, MA; Fairhurst, D; Griffiths, CE; Mendonca, CO; Smith, CH; Young, HS | 1 |
| Angioni, AR; Beck-Peccoz, P; Cattaneo, A; Lania, A; Spada, A | 1 |
| Bellavista, S; Iorizzo, M; Tosti, A; Vincenzi, C | 1 |
| Arican, O; Ozbulut, O; Sasmaz, S | 1 |
| Tey, HL; Theng, TS | 1 |
| Kathryn, M; Lebwohl, M | 1 |
| Menon, K; Siu, K; Strober, BE | 1 |
| Conley, J; Dhawan, S; Feldman, SR; Nanton, J; Pearce, DJ | 1 |
| Hodulik, SG; Zeichner, JA | 1 |
| Mahasitthiwat, V | 1 |
| Bravo Urbieta, J; Peña García, A; Serrano, C | 1 |
| Damasiewicz-Bodzek, A; Kos-Kudła, B; Suwała-Jurczyk, B | 1 |
| Feldman, SR; Klinger, S; Murad, EJ; Pearce, DJ; Rowell, R; Ziel, KK | 1 |
| Baïkian, B; Crickx, B; Descamps, V; Mahé, E; Toulon, A | 1 |
| Nikkels, AF; Piérard, GE | 1 |
| Pavel, S; Vermeer, MH; Vos, LE | 1 |
| Koo, J; Leon, A; Letsinger, J; Nguyen, A | 1 |
| Gyulai, R; Kemény, L | 1 |
| Girard, C; Guilhou, JJ | 1 |
| Bos, JD; Bossuyt, PM; de Rie, MA; deBorgie, CA; Heydendael, VM; Opmeer, BC; Spuls, PI | 1 |
| Chern, WH; Hofland, HE; Houlden, RJ; Hsia, E; Johnston, MJ | 1 |
| Abramovits, W; Cockerell, CJ; Larsen, F; Susa, JS | 1 |
| Asawanonda, P; Kampitak, T | 1 |
| Ezquerra, GM; Millet, PU; Regaña, MS | 1 |
| Rebora, A | 1 |
| De Jong, EM; Langewouters, AM; Van De Kerkhof, PC; Van Erp, PE | 1 |
| Clarke, JT; Clarke, S; George, R; Miller, JJ; Price, H | 1 |
| Avelleira, JC; Azulay, DR; Bastos, PR; Cruz, MA; de Oliveira, NC | 1 |
| Girolomoni, G; Gisondi, P | 1 |
| Daoud, L; Dhaoui, MR; Doss, N; Jaber, K; Youssef, S | 1 |
| Elston, CM; O'Toole, EA; Webber, NK | 1 |
| Brenner, FM; Bresch, M; Lima, HC; Werner, B | 1 |
| Horn, PJ; Kalb, RE; Lowenthal, KE | 1 |
| Dukic, R; Huber, M; Kieffer, C; Kieffer, P; Martzolff, L; Thannberger, P | 1 |
| Alegre de Miguel, V; Martínez Casimiro, L; Sánchez Carazo, JL | 1 |
| Cotena, C; Del Giglio, M; Girolomoni, G; Gisondi, P | 1 |
| Dohil, MA; Lam, J; Polifka, JE | 1 |
| Lebwohl, M; Menter, MA; Riddle, C; Smith, EC | 1 |
| Beutner, KR; Bhushan, R; Elmets, CA; Feldman, SR; Gordon, KB; Gottlieb, A; Koo, JY; Korman, NJ; Lebwohl, M; Leonardi, CL; Menter, A; Van Voorhees, AS | 1 |
| Ahdout, J; Chiu, M; Mandel, H | 1 |
| Lauharanta, J; Paravicini, U | 1 |
| Bauer, R; Orfanos, CE | 1 |
| Hirone, T; Ishizaki, H; Kaminaga, T; Kaseda, H; Masuda, H | 1 |
| DiGiovanna, JJ; Gantt, G; Gross, EG; McClean, SW; Peck, GL; Ruddel, ME | 1 |
| Larsen, FG | 1 |
| De Bersaques, J; De Leenheer, AP; Kint, AH; Lambert, WE; Meyer, E | 2 |
| Bjerke, JR; Degré, M; Gallati, H; Jablonska, S; Majewski, S; Matre, R; Tigalonova, M | 1 |
| Feldmann, R; Masgrau-Peya, E; Mesheit, J; Salomon, D; Saurat, JH | 1 |
| Burke, MD; Omar, G; Ormerod, AD; Shah, IA; Whiting, PH | 1 |
| Kullavanijaya, P; Kulthanan, K | 1 |
| Chichmanian, RM; Coschieri, M; Dor, JF; Philippon, A; Quinsat, D | 1 |
| Durand, A; Geiger, JM; Laugier, JP; Maibach, HI; Rufli, T; Surber, C | 1 |
| Berbis, P; Chemila, JF; Hesse, S; Privat, Y | 1 |
| Anderson, WB; Bouloc, A; Evain-Brion, D; Gerbaud, P; Gorin, I; Raynaud, F | 1 |
| Jakobsen, P; Knudsen, J; Kragballe, K; Larsen, FG; Nielsen-Kudsk, F; Weismann, K | 1 |
| Blum, A; Rassner, G; Scherwitz, C | 1 |
| Lindholm, A; Olsson, AG; Vahlquist, A; Vahlquist, C | 1 |
| Almond-Roesler, B; Orfanos, CE | 1 |
| Gerritsen, MJ; van de Kerkhof, PC; van Pelt, JP | 1 |
| Raymakers, RA; Steijlen, PM; van der Kerkhof, PC | 1 |
| Armstrong, DK; Burrows, D; Irvine, A; Mayne, EE; Walsh, MY | 1 |
| Gambla, C; Koo, J; Nguyen, Q | 1 |
| Bjerring, P; Heickendorff, L; Zachariae, H | 1 |
| Altmeyer, P; Nüchel, C | 1 |
| Kuijpers, AL; van de Kerkhof, PC; van Dooren-Greebe, JV | 1 |
| de Rooij, MJ; van de Kerkhof, PC | 1 |
| Bleiker, TO; Bourke, JF; Graham-Brown, RA; Hutchinson, PE | 1 |
| Buccheri, L; Cohen, SR; Karter, AJ; Katchen, BR | 1 |
| Katz, HI | 1 |
| Muchenberger, S; Schöpf, E; Simon, JC | 1 |
| Cambazard, F; Chalmers, RJ; Combemale, P; Damstra, RJ; Haneke, E; Hutchinson, PE; Neumann, MH; Olsen, L; Revuz, J; Souteyrand, P; van de Kerkhof, PC; Wong, E | 1 |
| Karamfilov, T; Wollina, U | 1 |
| Alatalo, E; Kontinen, J; Oikarinen, A; Röning, J; Savolainen, L | 1 |
| Bergers, M; Boegheim, PJ; Den Bakker, JE; Kuijpers, AL; Schalkwijk, J; Siegenthaler, G; Van de Kerkhof, PC; Van Pelt, JP | 1 |
| Bergman, R; Friedman-Birnbaum, R; Sprecher, E | 1 |
| Saurat, JH | 1 |
| Ling, MR | 1 |
| Roenigk, HH | 1 |
| Lebwohl, M | 1 |
| Koo, J | 1 |
| Armstrong, RB; Callen, JP; Fiedler, VC; Guzzo, CA; Katz, HI; Lowe, N; Madison, K; Nigra, T; Roenigk, HH | 1 |
| Apaydin, R; Başdaş, F; Bayramgürler, D; Bilen, N; Erçin, C; Harova, G | 1 |
| Orfanos, CE | 1 |
| Akasya, E; Baykal, C; Büyükbabani, N; Ozkaya-Bayazit, E | 1 |
| Koo, J; Liao, W | 1 |
| Akcan, Y; Bükülmez, G; Erkek, E; Karaduman, A; Sökmensüer, C | 1 |
| Feldman, S | 1 |
| van de Kerkhof, PC | 1 |
| Drake, L; Gottlieb, AB; Koo, J; Lebwohl, M; McClelland, P; Menter, A; Young, M; Zanolli, M | 1 |
| Ettler, K; Richards, B | 1 |
| Hönigsmann, H; Maier, H | 1 |
| Amin, S; Chopra, K; Kreiss, C; Nalesnik, MA; Shakil, AO | 1 |
| Andersson, E; Kragballe, K; Larsen, FG; Törma, H; Vahlquist, A; Vahlquist, C | 1 |
| Austad, J; Kolbenstvedt, A; Mørk, NJ | 1 |
| Brogden, RN; Pilkington, T | 1 |
| Detmar, M; Hettmannsperger, U; Kammler, HJ; Orfanos, CE; Owsianowski, M; Tenorio, S | 1 |
| Fritsch, PO | 1 |
| Lowe, N | 1 |
| Armstrong, R; Bourget, T; Edelstein, J; Lowe, NJ; Nychay, S; Prystowsky, JH | 1 |
| Anhalt, AW; Geiger, JM; Lessard, R; Murray, HE; Ross, JB; Schacter, RK; Stewart, WD | 1 |
| Eriksen, H; Grønhøj, J; Jakobsen, P; Kragballe, K; Larsen, FG; Nielsen-Kudsk, F | 1 |
| Fritsch, P; Geiger, JM; Guggenbichler, A; Hönigsmann, H; Tanew, A | 1 |
| Pihl-Lundin, I; Rollman, O | 1 |
| Braun-Falco, O; Köster, W; Lengen, W; Lensing, W; Letzel, H; Meigel, WN; Paul, E; Przybilla, B; Ruzicka, T; Sommerburg, C | 1 |
| Bitterling, T; Gollnick, H; Orfanos, CE; Rinck, G | 1 |
| Halioua, B; Saurat, JH | 1 |
| O'Brien, TJ | 1 |
| Berset, JD; Krebs, A | 1 |
| Saurat, JH; Siegenthaler, G | 1 |
| Mérot, Y; Salomon, D; Saurat, JH; Siegenthaler, G | 1 |
| Pihl-Lundin, I; Rollman, O; Vahlquist, A | 1 |
| Jansén, CT; Punnonen, K; Puustinen, T | 1 |
| Coble, BI; Dahlgren, C; Molin, L; Stendahl, O | 1 |
| Selinus, I; Vahlquist, C; Vessby, B | 1 |
| Chang, A; Geiger, JM; Happle, R; van de Kerkhof, PC; van Dooren-Greebe, R | 1 |
| Berbis, P; Geiger, JM; Privat, Y; Rognin, C; Vaisse, C | 1 |
| Ellis, CN; Goldfarb, MT; Gupta, AK; Voorhees, JJ | 1 |
| Boer, J; Iest, J | 1 |
| Geiger, JM; Lauharanta, J | 1 |
| Cobo, LM; Meyer, CJ; Olsen, EA; Weed, WW | 1 |
| Geiger, JM; Kádár, L; Török, L | 1 |
| Altmeyer, P; el-Gammal, S; Holzmann, H; Schröder, K; Zaun, H | 1 |
| Meffert, H; Sönnichsen, N | 1 |
| Bjerke, JR; Geiger, JM | 1 |
| Jakobsen, P; Kragballe, K; Larsen, FG; Nielsen-Kudsk, F | 1 |
| Berbis, P; Brindley, C; Bun, H; Durand, A; Geiger, JM; Laugier, JP; Privat, Y | 1 |
| Bjerke, JR; Falk, ES; Geiger, JM; Gip, L; Hjorth, N; Jansén, CT; Kragballe, K; Lauharanta, J; Mork, NJ; Reunala, T | 1 |
| Geiger, JM; Ingervo, L; Kaartamaa, M; Lassus, A; Nyblom, M; Virrankoski, T | 1 |
| Kingston, TP; Lowe, NJ; Matt, LH | 1 |
| Jakobsen, P; Larsen, CG; Larsen, FG | 1 |
| Jakobsen, P; Kragballe, K; Larsen, CG; Larsen, FG; Nielsen-Kudsk, F; Nørgaard, A | 1 |
| Vahlquist, A | 1 |
| Dicken, CH; Madhok, R; Muller, SA | 1 |
| Priestley, GC | 1 |
| Ellis, CN; Goldfarb, MT; Gupta, AK; Hamilton, TA; Tincoff, T; Voorhees, JJ | 1 |
| Jakobsen, P; Kragballe, K; Larsen, CG; Larsen, FG; Nielsen-Kudsk, F | 1 |
| Czarnetzki, BM; Geiger, JM | 1 |
| Alfin-Slater, RB; Ashley, JM; Borok, ME; Lowe, NJ | 1 |
| Lazarus, V; Lowe, NJ; Matt, L | 1 |
| Kilcoyne, RF | 1 |
| Bauer, R; Brindley, C; Gollnick, H; Hoting, E; Orfanos, CE; Plewig, G; Wokalek, H | 1 |
| Amblard, P; Beani, JC; Boulanger, A; Claudy, A; Frenk, E; Geiger, JM; Grosshans, E; Guilhou, JJ; Mérot, Y; Saurat, JH | 1 |
| Al Mallah, NR; Berbis, P; Bun, H; Durand, A; Geiger, JM; Privat, Y; Rognin, C | 1 |
| Geiger, JM; Ledo, A; Marrón, JM; Martín, M | 1 |
| Brindley, CJ; Geiger, JM | 1 |
| Gollnick, H; Orfanos, CE; Stadler, R; Tsambaos, D | 1 |
| Gollnick, H; Orfanos, CE | 1 |
91 review(s) available for acitretin and Palmoplantaris Pustulosis
| Article | Year |
|---|---|
Pustular psoriasis of pregnancy: Clinical and genetic characteristics in a series of eight patients and review of the literature.
Topics: Acitretin; Adult; CARD Signaling Adaptor Proteins; Cyclosporine; Female; Guanylate Cyclase; Humans; Infant; Infant, Newborn; Interleukins; Membrane Proteins; Pregnancy; Psoriasis; Retrospective Studies; Skin Diseases, Vesiculobullous; Steroids; Young Adult | 2022 |
Efficacy of adalimumab in pediatric generalized pustular psoriasis: case series and literature review.
Topics: Acitretin; Acute Disease; Adalimumab; Adult; Child; Chronic Disease; Humans; Methotrexate; Psoriasis; Skin Diseases, Vesiculobullous | 2022 |
Efficacy and safety of external application of Chinese herbal medicine for psoriasis vulgaris: a systematic review of randomized controlled trials.
Topics: Acitretin; Drugs, Chinese Herbal; Humans; Ointments; Psoriasis; Randomized Controlled Trials as Topic | 2022 |
A Meta-analysis of Xiaoyin Granules Combined with Acitretin Capsule in the Treatment of Psoriasis Vulgaris.
Topics: Acitretin; Chronic Disease; Combined Modality Therapy; Drugs, Chinese Herbal; Humans; Psoriasis | 2022 |
Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review.
Topics: Acitretin; Adrenal Cortex Hormones; Anti-Bacterial Agents; Azathioprine; Biological Factors; Biological Products; Cyclosporins; Dermatologic Agents; Etanercept; Humans; Immunosuppressive Agents; Methotrexate; Niacinamide; Pemphigoid, Bullous; Psoriasis; Rituximab; Ustekinumab; Vitamins | 2022 |
An update on therapeutic options for palmoplantar pustulosis: a narrative review and expert recommendations.
Topics: Acitretin; Chronic Disease; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Psoriasis | 2023 |
Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review.
Topics: Acitretin; Endonucleases; Humans; Methotrexate; Pharmacogenetics; Psoriasis; Tumor Necrosis Factor Inhibitors | 2023 |
Translating the 2020 AAD-NPF Guidelines of Care for the Management of Psoriasis With Systemic Nonbiologics to Clinical Practice.
Topics: Acitretin; Adult; Cyclosporine; Humans; Methotrexate; Psoriasis; United States | 2021 |
Management of pediatric psoriasis with acitretin: A review.
Topics: Acitretin; Adolescent; Age of Onset; Child; Child, Preschool; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Male; Psoriasis; Skin; Treatment Outcome | 2018 |
Efficacy and safety of acitretin monotherapy in children with pustular psoriasis: results from 15 cases and a literature review.
Topics: Acitretin; Child; Child, Preschool; Databases, Factual; Female; Humans; Infant; Keratolytic Agents; Male; Psoriasis; Severity of Illness Index; Treatment Outcome | 2018 |
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
Topics: Acitretin; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Certolizumab Pegol; Cyclosporine; Dermatologic Agents; Etanercept; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Psoriasis; Thalidomide; Ustekinumab | 2018 |
Pharmacokinetics of tazarotene and acitretin in psoriasis.
Topics: Acitretin; Administration, Cutaneous; Administration, Oral; Animals; Dermatologic Agents; Humans; Keratolytic Agents; Medication Adherence; Nicotinic Acids; Psoriasis; Treatment Outcome | 2018 |
Commentary to the review article: Subedi S, Yu Q, Chen Z, Shi Y. Management of pediatric psoriasis with acitretin: A review. Dermatol Ther. 2018 Jan;31(1).
Topics: Acitretin; Child; Drug Therapy, Combination; Humans; Keratolytic Agents; Psoriasis | 2018 |
Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review.
Topics: Acitretin; Adult; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Fumarates; Humans; Methotrexate; Multicenter Studies as Topic; Observational Studies as Topic; Psoriasis; Severity of Illness Index; Treatment Outcome | 2019 |
Secukinumab (Cosentyx°) and plaque psoriasis.
Topics: Acitretin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Cyclosporine; Etanercept; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Psoriasis; PUVA Therapy; Severity of Illness Index; Treatment Failure; Tumor Necrosis Factor-alpha; Ultraviolet Therapy | 2017 |
Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus.
Topics: Acitretin; Administration, Oral; Administration, Topical; Adult; Aged; Biological Products; Consensus; Cyclosporine; Dermatologic Agents; Disease Management; Expert Testimony; Female; Humans; Injections, Intralesional; Male; Methotrexate; Middle Aged; Nail Diseases; Practice Guidelines as Topic; Psoriasis; Recurrence; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2019 |
Moderate to severe plaque psoriasis - treatment with drugs of the classic scheme.
Topics: Acitretin; Antibodies, Monoclonal; Brazil; Clinical Decision-Making; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Methotrexate; Psoriasis; Severity of Illness Index; Time Factors; Treatment Outcome | 2019 |
Secondary bilateral striopallidodentate calcinosis associated with generalized pustular psoriasis (Von Zumbusch).
Topics: Acitretin; Adult; Bacteremia; Basal Ganglia Diseases; Calcinosis; Calcium; Drug Therapy, Combination; Epilepsy; Floxacillin; Humans; Hyperphosphatemia; Hypocalcemia; Male; Methicillin-Resistant Staphylococcus aureus; Nails, Ingrown; Neurodegenerative Diseases; Parathyroid Hormone; Postoperative Complications; Pseudohypoparathyroidism; Psoriasis; Staphylococcal Infections; Tomography, X-Ray Computed; Vitamin D | 2013 |
From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
Topics: Acitretin; Antibodies, Monoclonal, Humanized; Biological Therapy; Cardiovascular Diseases; Cyclosporine; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Mycophenolic Acid; Psoriasis; PUVA Therapy; Tumor Necrosis Factor-alpha; Ustekinumab | 2014 |
Psoriasis.
Topics: Acitretin; Administration, Topical; Cardiovascular Diseases; Cyclosporine; Dermatologic Agents; Humans; Methotrexate; Phototherapy; Psoriasis; Tumor Necrosis Factor-alpha | 2013 |
Acitretin in psoriasis: an evolving scenario.
Topics: Acitretin; Drug Therapy, Combination; Humans; Psoriasis | 2014 |
Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion.
Topics: Acitretin; Adrenal Cortex Hormones; Cyclosporine; Dermatologic Agents; Evidence-Based Medicine; Humans; Keratolytic Agents; Photochemotherapy; Practice Guidelines as Topic; Psoriasis | 2014 |
Oral Chinese herbal medicine combined with pharmacotherapy for psoriasis vulgaris: a systematic review.
Topics: Acitretin; Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Keratolytic Agents; Lithospermum; Phytotherapy; Plant Roots; Psoriasis; Randomized Controlled Trials as Topic; Rehmannia; Salvia miltiorrhiza | 2014 |
Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities.
Topics: Acitretin; Adipokines; Alcoholism; Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Comorbidity; Cyclosporine; Dermatologic Agents; Diabetes Mellitus; Fumarates; Humans; Immunosuppressive Agents; Inflammation; Metabolic Syndrome; Methotrexate; Obesity; Psoriasis; Risk Factors; Smoking; Tumor Necrosis Factor-alpha; Ustekinumab | 2015 |
Current and future oral systemic therapies for psoriasis.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Cyclosporine; Fumarates; Humans; Hydroxyurea; Immunosuppressive Agents; Isoxazoles; Keratolytic Agents; Leflunomide; Methotrexate; Mycophenolic Acid; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Sulfasalazine; Thalidomide; Thioguanine | 2015 |
Pharmacogenomics and the resulting impact on psoriasis therapies.
Topics: Acitretin; Cyclosporine; Cytokines; HLA-C Antigens; Humans; Immunosuppressive Agents; Inflammation; Keratolytic Agents; Methotrexate; Pharmacogenetics; Phototherapy; Polymorphism, Genetic; Precision Medicine; Psoriasis; Research Design; Tumor Necrosis Factor-alpha | 2015 |
Etanercept combined with systemic drugs or phototherapy for treatment of psoriasis.
Topics: Acitretin; Antirheumatic Agents; Clinical Trials as Topic; Cyclosporine; Drug Therapy, Combination; Etanercept; Humans; Methotrexate; Multicenter Studies as Topic; Prospective Studies; Psoriasis; Treatment Outcome; Ultraviolet Therapy | 2015 |
Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments.
Topics: Acitretin; Administration, Cutaneous; Adrenal Cortex Hormones; Calcineurin Inhibitors; Calcitriol; Coal Tar; Contraindications; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Methotrexate; Nicotinic Acids; Pregnancy; Pregnancy Complications; Psoriasis; PUVA Therapy; Tumor Necrosis Factor-alpha; Ultraviolet Therapy; Ustekinumab | 2015 |
Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Cyclosporine; Disease Progression; Humans; Immunosuppressive Agents; Insurance, Health, Reimbursement; Keratolytic Agents; Medication Adherence; Methotrexate; Psoriasis; Symptom Flare Up; Thalidomide | 2016 |
Ultraviolet B Phototherapy for Psoriasis: Review of Practical Guidelines.
Topics: Acitretin; Administration, Topical; Combined Modality Therapy; Contraindications; Dermatologic Agents; Dose-Response Relationship, Radiation; Humans; Interleukin-17; Keratolytic Agents; Lasers, Excimer; Low-Level Light Therapy; Methotrexate; Phosphodiesterase Inhibitors; Practice Guidelines as Topic; Psoriasis; PUVA Therapy; Skin; Tumor Necrosis Factor-alpha; Ultraviolet Therapy | 2016 |
Is Oral Chinese Herbal Medicine Beneficial for Psoriasis Vulgaris? A Meta-Analysis of Comparisons with Acitretin.
Topics: Acitretin; Administration, Oral; Adolescent; Adult; Aged; Drugs, Chinese Herbal; Female; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis; Randomized Controlled Trials as Topic; Young Adult | 2016 |
Idiopathic CD4 T-Cell Lymphocytopenia: A Case Report of a Young Boy With Recalcitrant Warts.
Topics: Acitretin; CD4 Lymphocyte Count; Child; Cryotherapy; Dermatologic Agents; Humans; Keratolytic Agents; Lymphopenia; Male; Psoriasis; Retreatment; Warts | 2016 |
Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects.
Topics: Acitretin; Adrenal Cortex Hormones; Biological Products; Chronic Disease; Dermatologic Agents; Hand Dermatoses; Humans; Phototherapy; Psoriasis; Quality of Life | 2016 |
Pathophysiological basis of systemic treatments in psoriasis.
Topics: Acitretin; Arthritis, Psoriatic; Biosimilar Pharmaceuticals; Dermatologic Agents; Humans; Psoriasis | 2016 |
Advances in Psoriasis.
Topics: Acitretin; Administration, Topical; Adrenal Cortex Hormones; Cyclosporine; Dermatologic Agents; Humans; Interleukins; Methotrexate; Phototherapy; Psoriasis; PUVA Therapy; Tumor Necrosis Factor-alpha; Vitamin D | 2017 |
An updated review of acitretin--a systemic retinoid for the treatment of psoriasis.
Topics: Acitretin; Animals; Drug Therapy, Combination; Humans; Immunocompromised Host; Keratolytic Agents; Psoriasis | 2008 |
Repigmentation and curling of hair after acitretin therapy.
Topics: Acitretin; Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Hair; Hair Color; Humans; Hyperpigmentation; Keratolytic Agents; Psoriasis; Severity of Illness Index | 2009 |
A review of acitretin for the treatment of psoriasis.
Topics: Acitretin; Drug Interactions; Drug Therapy, Combination; Drug Utilization; Humans; Keratolytic Agents; Psoriasis | 2009 |
Treatment of acrodermatitis continua of Hallopeau with TNF-blocking agents: case report and review.
Topics: Acitretin; Acrodermatitis; Adalimumab; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Betamethasone; Clobetasol; Cyclosporine; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Methotrexate; Mycophenolic Acid; Nails; Paronychia; Psoriasis; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor Inhibitors | 2010 |
British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology.
Topics: Acitretin; Drug Interactions; Drug Monitoring; Evidence-Based Medicine; Humans; Ichthyosis; Keratolytic Agents; Psoriasis; Skin Diseases | 2010 |
Acitretin revisited in the era of biologics.
Topics: Acitretin; Drug Therapy, Combination; Humans; Keratolytic Agents; Psoriasis | 2011 |
Pharmacogenetics of psoriasis.
Topics: Acitretin; Adrenal Cortex Hormones; Antibodies, Monoclonal; Cyclosporine; Genetic Predisposition to Disease; Humans; Methotrexate; Pharmacogenetics; Precision Medicine; Psoriasis | 2011 |
A review of phototherapy protocols for psoriasis treatment.
Topics: Acitretin; Carotid Stenosis; Clinical Protocols; Humans; Immunosuppressive Agents; Keratolytic Agents; Lasers, Excimer; Methotrexate; Psoriasis; PUVA Therapy; Treatment Outcome; Ultraviolet Therapy | 2011 |
Depression and acitretin: a true association or a class labeling?
Topics: Acitretin; Depression; Dermatologic Agents; Drug Labeling; Humans; Isotretinoin; Mood Disorders; Psoriasis; Suicidal Ideation; Suicide; United States; United States Food and Drug Administration | 2011 |
A case of verrucous psoriasis.
Topics: Acitretin; Administration, Topical; Adrenal Cortex Hormones; Aged, 80 and over; Alopecia; Diagnosis, Differential; Female; Humans; Keratosis, Seborrheic; Psoriasis; Recurrence; Skin Neoplasms | 2011 |
What's new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010.
Topics: Acitretin; Anti-Inflammatory Agents; Biological Therapy; Humans; Keratolytic Agents; Practice Guidelines as Topic; Psoriasis; Severity of Illness Index | 2011 |
Acitretin in dermatology: a review.
Topics: Acitretin; Humans; Keratolytic Agents; Off-Label Use; Psoriasis; Skin Diseases; Skin Neoplasms | 2011 |
Efficacy of low-dose acitretin in the treatment of psoriasis.
Topics: Acitretin; Adult; Body Surface Area; Female; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis; Treatment Outcome | 2012 |
The effects of alcohol on the metabolism and toxicology of anti-psoriasis drugs.
Topics: Acitretin; Administration, Topical; Alcohol Drinking; Chronic Disease; Ethanol; Etretinate; Folic Acid Antagonists; Humans; Keratolytic Agents; Psoriasis; Skin | 2012 |
Rapid downregulation of innate immune cells, interleukin-12 and interleukin-23 in generalized pustular psoriasis with infliximab in combination with acitretin.
Topics: Acitretin; Aged; Antibodies, Monoclonal; Down-Regulation; Drug Therapy, Combination; Humans; Infliximab; Interleukin-12; Interleukin-23; Male; Psoriasis; Treatment Outcome | 2012 |
Comparative tolerability of systemic treatments for plaque-type psoriasis.
Topics: Acitretin; Cyclosporine; Dermatologic Agents; Drug Combinations; Eye Diseases; Humans; Keratolytic Agents; Liver Cirrhosis; Lymphoproliferative Disorders; Methotrexate; Nausea; Pancytopenia; Pneumonia; Pruritus; Psoriasis; PUVA Therapy; Skin Neoplasms | 2002 |
Vitamin D and systemic therapy.
Topics: Acitretin; Administration, Oral; Administration, Topical; Calcitriol; Clinical Trials as Topic; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Humans; Keratolytic Agents; Methotrexate; Ointments; Psoriasis | 2002 |
Agranulocytosis and total scalp alopecia following acitretin.
Topics: Acitretin; Acute Disease; Aged; Aged, 80 and over; Agranulocytosis; Alopecia; Female; Humans; Keratolytic Agents; Psoriasis | 2003 |
Current systemic therapies for psoriasis: where are we now?
Topics: Acitretin; Antineoplastic Agents; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Humans; Hydroxyurea; Keratolytic Agents; Methotrexate; Psoriasis; Remission Induction | 2003 |
Phototherapy treatment of psoriasis today.
Topics: Acitretin; Humans; Keratolytic Agents; Office Visits; Photochemotherapy; Phototherapy; Psoriasis; Ultraviolet Therapy | 2003 |
Acitretin suppression of squamous cell carcinoma: case report and literature review.
Topics: Acitretin; Adult; Carcinoma, Squamous Cell; Humans; Keratolytic Agents; Male; Psoriasis; PUVA Therapy; Skin Neoplasms; Treatment Outcome | 2003 |
Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis.
Topics: Acitretin; Cyclosporine; Drug Therapy, Combination; Etretinate; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Phototherapy; Psoriasis; Recombinant Fusion Proteins; Treatment Outcome | 2003 |
Combination therapy to treat moderate to severe psoriasis.
Topics: Acitretin; Calcitriol; Drug Therapy, Combination; Humans; Methotrexate; Psoriasis; PUVA Therapy | 2004 |
Combining traditional agents and biologics for the treatment of psoriasis.
Topics: Acitretin; Adalimumab; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Clinical Trials as Topic; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Infliximab; Methotrexate; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins | 2005 |
A review of acitretin, a systemic retinoid for the treatment of psoriasis.
Topics: Acitretin; Animals; Drug Therapy, Combination; Humans; Phototherapy; Psoriasis; Retinoids | 2005 |
New roles for systemic retinoids.
Topics: Acitretin; Administration, Oral; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Graft Survival; Humans; Keratolytic Agents; Male; Organ Transplantation; Prognosis; Psoriasis; Retinoids; Risk Assessment; Skin Diseases; Treatment Outcome | 2006 |
Conventional systemic agents for psoriasis. A systematic review.
Topics: Acitretin; Clinical Trials as Topic; Cyclosporine; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hydroxyurea; Immunosuppressive Agents; Methotrexate; Practice Guidelines as Topic; Psoriasis; Thioguanine; Treatment Outcome | 2006 |
Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis.
Topics: Acitretin; Drug Administration Schedule; Humans; Keratolytic Agents; Psoriasis; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index | 2006 |
An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options.
Topics: Acitretin; Adalimumab; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Biological Therapy; Dermatologic Agents; Evidence-Based Medicine; Humans; Methotrexate; Psoriasis; PUVA Therapy; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins | 2007 |
[The immunology of psoriasis: from basic research to the bedside].
Topics: Acitretin; Adrenal Cortex Hormones; Alefacept; Anthralin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Autoimmunity; Biomedical Research; Cell Differentiation; Cell Proliferation; Cyclosporine; Dermatologic Agents; Humans; Immunity, Cellular; Immunosuppressive Agents; Infliximab; Keratinocytes; Keratolytic Agents; Methotrexate; Psoriasis; Recombinant Fusion Proteins; T-Lymphocytes, Regulatory; Ultraviolet Therapy | 2006 |
[Psoriasis].
Topics: Acitretin; Adrenal Cortex Hormones; Adult; Age Factors; Arthritis, Psoriatic; Calcitriol; Child; Cyclosporine; Dermatologic Agents; Diagnosis, Differential; HIV Infections; Humans; Infant; Infant, Newborn; Keratolytic Agents; Methotrexate; Ointments; Phototherapy; Psoriasis; Skin; Time Factors; Vitamins | 2006 |
[Long-term control of psoriasis is necessary].
Topics: Acitretin; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Biological Products; Combined Modality Therapy; Comorbidity; Cyclosporine; Cytokines; Dermatologic Agents; Humans; Immunosuppressive Agents; Infliximab; Methotrexate; Middle Aged; Psoriasis; PUVA Therapy; Quality of Life; Recurrence | 2008 |
Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases.
Topics: Acitretin; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Immunologic Factors; Keratolytic Agents; Pregnancy; Pregnancy Complications; Product Surveillance, Postmarketing; Psoriasis; Skin Diseases; Teratogens | 2008 |
Evidence for anti-inflammatory activities of oral synthetic retinoids: experimental findings and clinical experience.
Topics: Acitretin; Administration, Oral; Animals; Anti-Inflammatory Agents; Etretinate; Granulocytes; Humans; Isotretinoin; Leukocyte Count; Lymphocytes; Macrophages; Mice; Psoriasis; Skin Diseases; Skin Temperature; Tretinoin | 1983 |
Pharmacokinetics of etretinate and acitretin with special reference to treatment of psoriasis.
Topics: Absorption; Acitretin; Etretinate; Humans; Methotrexate; Psoriasis; Vitamin A | 1994 |
[Trans-acitretin is metabolized back to etretinate. Importance for oral retinoid therapy].
Topics: Acitretin; Administration, Oral; Animals; Biotransformation; Drug Monitoring; Esterification; Etretinate; Female; Half-Life; Humans; Keratolytic Agents; Pregnancy; Psoriasis; Treatment Outcome | 1996 |
Advances in psoriasis therapy.
Topics: Absorption; Acitretin; Administration, Cutaneous; Calcitriol; Chemistry, Pharmaceutical; Clinical Trials as Topic; Cyclosporine; Dermatologic Agents; Humans; Immunosuppressive Agents; Keratolytic Agents; Ointments; Psoriasis | 1997 |
[Systemic therapy of psoriasis].
Topics: Acitretin; Cyclosporine; Dermatologic Agents; Fumarates; Glucocorticoids; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Photochemotherapy; Phototherapy; Psoriasis | 1996 |
Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis.
Topics: Acitretin; Aged; Aged, 80 and over; Calcitriol; Cyclosporine; Dermatitis, Exfoliative; Dermatologic Agents; Drug Combinations; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Methotrexate; Middle Aged; Prognosis; Psoriasis | 1997 |
Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris: review of the literature and results of a survey sent to 100 dermatologists.
Topics: Acitretin; Administration, Topical; Calcitriol; Combined Modality Therapy; Cyclosporine; Dermatologic Agents; Drug Synergism; Drug Therapy, Combination; Etretinate; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Ointments; Phototherapy; Psoriasis; Risk; Safety; Treatment Outcome | 1997 |
Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment.
Topics: Acitretin; Animals; Humans; Interferon-gamma; Keratolytic Agents; Mice; Psoriasis; Receptors, Cytoplasmic and Nuclear; Retinoids; Skin; Vitamin D | 1999 |
Acitretin: optimal dosing strategies.
Topics: Acitretin; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Keratolytic Agents; Psoriasis | 1999 |
Acitretin combination therapy.
Topics: Acitretin; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Humans; Keratolytic Agents; Methotrexate; Psoriasis; PUVA Therapy; Ultraviolet Therapy | 1999 |
Acitretin in combination with UVB or PUVA.
Topics: Acitretin; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Keratolytic Agents; Psoriasis; PUVA Therapy; Treatment Outcome; Ultraviolet Therapy | 1999 |
Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results.
Topics: Acitretin; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Keratolytic Agents; Methotrexate; Psoriasis | 1999 |
Treatment of psoriasis with retinoids: present status.
Topics: Acitretin; Etretinate; Humans; Keratolytic Agents; Psoriasis; Retinoids | 1999 |
Pustular psoriasis with a striking linear pattern.
Topics: Acitretin; Arm; Chronic Disease; Diagnosis, Differential; Female; Humans; Keratolytic Agents; Middle Aged; Psoriasis; Skin | 2000 |
Update on psoriasis therapy: a perspective from the USA.
Topics: Acitretin; Calcitriol; Clobetasol; Cyclosporine; Dermatologic Agents; Humans; Photochemotherapy; Psoriasis; United States | 2000 |
Advances in psoriasis treatment.
Topics: Acitretin; Administration, Topical; Anthralin; Anti-Inflammatory Agents; Coal Tar; Cyclosporine; Dermatologic Agents; Glucocorticoids; Humans; Methotrexate; Nicotinic Acids; Patient Education as Topic; Phototherapy; Psoriasis; PUVA Therapy; Quality of Life; Social Support; Triamcinolone | 2000 |
Therapeutic strategies: rotational therapy and combinations.
Topics: Acitretin; Administration, Topical; Anti-Inflammatory Agents; Autoimmune Diseases; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Therapy, Combination; Fumarates; Glucocorticoids; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Phototherapy; Psoriasis; PUVA Therapy | 2001 |
Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis.
Topics: Acitretin; Administration, Topical; Chronic Disease; Clinical Trials as Topic; Combined Modality Therapy; Humans; Keratolytic Agents; Practice Guidelines as Topic; Prognosis; Psoriasis; Ultraviolet Therapy | 2001 |
Acitretin. A review of its pharmacology and therapeutic use.
Topics: Acitretin; Animals; Humans; Psoriasis; Tretinoin | 1992 |
Retinoids in psoriasis and disorders of keratinization.
Topics: Acitretin; Etretinate; Humans; Ichthyosis; Keratosis; Psoriasis | 1992 |
Risk: benefit ratio in the treatment of psoriasis with systemic retinoids.
Topics: Abnormalities, Drug-Induced; Acitretin; Adult; Aged; Bone Diseases; Chemical and Drug Induced Liver Injury; Etretinate; Eye Diseases; Female; Humans; Lipids; Male; Middle Aged; Psoriasis; Risk Factors; Skin Diseases; Tretinoin | 1990 |
Systemic retinoid therapy for psoriasis.
Topics: Acitretin; Etretinate; Humans; Isomerism; Isotretinoin; Psoriasis; Tretinoin | 1988 |
Current developments of oral retinoid therapy with three generations of drugs. Non-aromatic, monoaromatic and polyaromatic retinoids (arotinoids).
Topics: Acitretin; Administration, Oral; Benzoates; Eczema; Etretinate; Humans; Isotretinoin; Psoriasis; Retinoids; Skin Diseases; Skin Diseases, Vesiculobullous; Tretinoin | 1985 |
60 trial(s) available for acitretin and Palmoplantaris Pustulosis
| Article | Year |
|---|---|
Research "recover from illness defense complex" helper T cell immune mechanisms based on the "Fuxie" theory clearing away heat evil thoroughly nourishing kidney treatment of recurrent blood-heat syndrome Psoriasis.
Topics: Acitretin; Administration, Oral; Adolescent; Adult; Aged; Case-Control Studies; Cytokines; Drugs, Chinese Herbal; Female; Heat Exhaustion; Hot Temperature; Humans; Immunity, Cellular; Keratolytic Agents; Male; Middle Aged; Outcome Assessment, Health Care; Psoriasis; Quality of Life; Recurrence; Severity of Illness Index; T-Lymphocytes, Helper-Inducer; Young Adult | 2020 |
Short- and long-term efficacy of fumaric acid esters or acitretin in combination with a 12-week course of PUVA in the treatment of palmoplantar pustulosis: results from a prospective randomized trial.
Topics: Acitretin; Fumarates; Humans; Prospective Studies; Psoriasis; PUVA Therapy; Treatment Outcome | 2021 |
Safety and efficacy profile of oral cyclosporine vs oral methotrexate vs oral acitretin in palmoplantar psoriasis: A hospital based prospective investigator blind randomized controlled comparative study.
Topics: Acitretin; Cyclosporine; Hospitals; Humans; Methotrexate; Prospective Studies; Psoriasis; Quality of Life; Severity of Illness Index; Treatment Outcome | 2021 |
Efficacy and safety of total glucosides of paeony combined with acitretin in the treatment of moderate-to-severe plaque psoriasis: a double-blind, randomised, placebo-controlled trial.
Topics: Acitretin; Adult; Alanine Transaminase; Chemical and Drug Induced Liver Injury; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Keratolytic Agents; Male; Middle Aged; Paeonia; Phytotherapy; Plant Extracts; Plant Roots; Protective Factors; Psoriasis; Severity of Illness Index | 2017 |
Curcumin nanoparticles potentiate therapeutic effectiveness of acitrein in moderate-to-severe psoriasis patients and control serum cholesterol levels.
Topics: Acitretin; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cholesterol; Curcumin; Double-Blind Method; Drug Stability; Drug Synergism; Female; Humans; Keratolytic Agents; Male; Membranes, Artificial; Middle Aged; Nanoparticles; Permeability; Psoriasis; Severity of Illness Index; Surface Properties; Young Adult | 2018 |
Polymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to acitretin in psoriasis patients.
Topics: Acitretin; Adult; China; HEK293 Cells; Humans; Keratolytic Agents; Liver-Specific Organic Anion Transporter 1; Middle Aged; Organic Cation Transporter 1; Pharmacogenomic Variants; Polymorphism, Genetic; Psoriasis; Treatment Outcome | 2018 |
Oxymatrine therapy inhibited epidermal cell proliferation and apoptosis in severe plaque psoriasis.
Topics: Acitretin; Adult; Alkaloids; Apoptosis; Biopsy; Cell Proliferation; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Keratinocytes; Male; Psoriasis; Quinolizines; Severity of Illness Index; Skin; Treatment Outcome; Young Adult | 2019 |
Plasma miR-126 expression correlates with risk and severity of psoriasis and its high level at baseline predicts worse response to Tripterygium wilfordii Hook F in combination with acitretin.
Topics: Acitretin; Adult; Female; Gene Expression Regulation; Humans; Keratolytic Agents; Male; MicroRNAs; Middle Aged; Plant Extracts; Psoriasis; Risk Factors; Treatment Outcome; Tripterygium | 2019 |
The effect of acitretin treatment on insulin resistance, retinol-binding protein-4, leptin, and adiponectin in psoriasis vulgaris: a noncontrolled study.
Topics: Acitretin; Adiponectin; Adult; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Insulin; Insulin Resistance; Leptin; Male; Psoriasis; Retinol-Binding Proteins, Plasma | 2013 |
Serum concentrations of interleukin-2 and tumour necrosis factor-α under cyclosporine versus acitretin treatment in plaque-type psoriasis.
Topics: Acitretin; Adult; Biomarkers; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Interleukin-2; Keratolytic Agents; Male; Middle Aged; Prognosis; Prospective Studies; Psoriasis; Severity of Illness Index; Tumor Necrosis Factor-alpha; Young Adult | 2014 |
Efficacy and safety of Tripterygium wilfordii hook F versus acitretin in moderate to severe psoriasis vulgaris: a randomized clinical trial.
Topics: Acitretin; Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Plant Extracts; Psoriasis; Treatment Outcome; Tripterygium; Young Adult | 2015 |
A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients
Topics: Acitretin; Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Immunosuppressive Agents; Keratolytic Agents; Korea; Male; Middle Aged; Pilot Projects; Psoriasis; Receptors, Tumor Necrosis Factor; Severity of Illness Index | 2016 |
Efficacy of oxymatrine for treatment and relapse suppression of severe plaque psoriasis: results from a single-blinded randomized controlled clinical trial.
Topics: Acitretin; Adult; Alkaloids; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Keratolytic Agents; Male; Psoriasis; Quality of Life; Quinolizines; Secondary Prevention; Single-Blind Method; Treatment Outcome | 2017 |
Adherence to acitretin and home narrowband ultraviolet B phototherapy in patients with psoriasis.
Topics: Acitretin; Administration, Oral; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Patient Compliance; Psoriasis; Ultraviolet Therapy | 2008 |
Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial.
Topics: Acitretin; Adult; Aged; Etanercept; Female; Humans; Immunoglobulin G; Immunosuppressive Agents; Interleukin-17; Interleukin-22; Interleukin-23; Interleukins; Keratolytic Agents; Male; Middle Aged; Psoriasis; Receptors, Tumor Necrosis Factor; Severity of Illness Index | 2009 |
A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis.
Topics: Acitretin; Adult; Female; Humans; Keratolytic Agents; Male; Phototherapy; Prospective Studies; Psoriasis; PUVA Therapy; Severity of Illness Index; Treatment Outcome | 2008 |
Evaluation of the efficacy of acitretin therapy for nail psoriasis.
Topics: Acitretin; Adult; Aged; Female; Humans; Keratolytic Agents; Male; Middle Aged; Nail Diseases; Psoriasis | 2009 |
Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Acitretin; Adolescent; Adult; Aged; Dermatologic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pioglitazone; Psoriasis; Thiazolidinediones; Young Adult | 2009 |
Effect of Chinese herbal medicine combined with acitretin capsule in treating psoriasis of blood-heat syndrome type.
Topics: Acitretin; Adult; Aged; Capsules; Combined Modality Therapy; Diagnosis, Differential; Drug Combinations; Drugs, Chinese Herbal; Female; Hematologic Diseases; Hot Temperature; Humans; Keratolytic Agents; Male; Medicine, Chinese Traditional; Middle Aged; Psoriasis; Syndrome; Treatment Outcome; Young Adult | 2009 |
Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis.
Topics: Acitretin; Administration, Cutaneous; Adult; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Double-Blind Method; Drug Carriers; Drug Compounding; Female; Gels; Humans; In Vitro Techniques; Lipids; Male; Middle Aged; Nanostructures; Particle Size; Psoriasis; Skin Absorption; X-Ray Diffraction | 2010 |
A global approach to psoriatic patients through PASI score and Skindex-29.
Topics: Acitretin; Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Diagnostic Self Evaluation; Emotions; Etanercept; Female; Folic Acid; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Interpersonal Relations; Male; Methotrexate; Middle Aged; Psoriasis; PUVA Therapy; Quality of Life; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2011 |
Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study.
Topics: Acitretin; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis; Young Adult | 2013 |
Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study.
Topics: Acitretin; Adolescent; Adult; Foot; Hand; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Middle Aged; Prospective Studies; Psoriasis; Treatment Outcome; Young Adult | 2013 |
Efficacy of acitretin and commercial tanning bed therapy for psoriasis.
Topics: Acitretin; Adult; Aged; Combined Modality Therapy; Female; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis; Retrospective Studies; Ultraviolet Therapy | 2003 |
The efficacy of calcipotriol + acitretin combination therapy for psoriasis: comparison with acitretin monotherapy.
Topics: Acitretin; Adult; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis | 2003 |
Combination of acitretin and oral calcitriol for treatment of plaque-type psoriasis.
Topics: Acitretin; Administration, Oral; Aged; Calcitriol; Drug Therapy, Combination; Female; Humans; Keratolytic Agents; Male; Middle Aged; Prospective Studies; Psoriasis; Severity of Illness Index; Vitamins | 2007 |
The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis.
Topics: Acitretin; Adult; Aged; Alefacept; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Recombinant Fusion Proteins; Treatment Outcome | 2006 |
Comparative study of histopathological and immunohistochemical findings in skin biopsies from patients with psoriasis before and after treatment with acitretin.
Topics: Acitretin; Adult; Biomarkers; Biopsy; Cell Count; Female; Humans; Keratinocytes; Keratins; Keratolytic Agents; Langerhans Cells; Male; Middle Aged; Prospective Studies; Psoriasis; Skin; Treatment Outcome | 2008 |
Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Drug Administration Schedule; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Keratolytic Agents; Male; Middle Aged; Pilot Projects; Psoriasis; Quality of Life; Receptors, Tumor Necrosis Factor; Single-Blind Method; Time Factors; Treatment Outcome | 2008 |
Etretinate: effect of milk intake on absorption.
Topics: Acitretin; Animals; Darier Disease; Etretinate; Humans; Milk; Psoriasis; Tretinoin; Water | 1984 |
Clinical efficacy and side effects of acitretin on the disorders of keratinization: a one-year study.
Topics: Acitretin; Adolescent; Adult; Bone and Bones; Female; Humans; Keratosis; Lipid Metabolism; Liver; Liver Function Tests; Male; Prospective Studies; Psoriasis; Time Factors | 1993 |
Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study.
Topics: Acitretin; Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Keratolytic Agents; Lipoproteins; Lipoproteins, VLDL; Male; Middle Aged; Placebos; Psoriasis; Triglycerides | 1995 |
Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection.
Topics: Acitretin; Adult; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Pilot Projects; Psoriasis | 1997 |
The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis.
Topics: Acitretin; Adult; Calcitriol; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Keratolytic Agents; Male; Middle Aged; Ointments; Psoriasis; Treatment Outcome | 1998 |
The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin.
Topics: Acitretin; Administration, Oral; Adult; Aged; Cell Differentiation; Cell Division; Double-Blind Method; Epidermis; Female; Humans; Imidazoles; Immunoenzyme Techniques; Keratolytic Agents; Leukocyte Count; Male; Middle Aged; Proteinase Inhibitory Proteins, Secretory; Proteins; Psoriasis; Serine Proteinase Inhibitors | 1998 |
Effects of acitretin on the liver.
Topics: Acitretin; Adult; Biopsy; Female; Humans; Keratolytic Agents; Liver; Male; Prospective Studies; Psoriasis | 1999 |
Assessment of acitretin-treated female patients of childbearing age and subsequent risk of teratogenicity.
Topics: Acitretin; Adult; Biotransformation; Ethanol; Etretinate; Female; Humans; Keratolytic Agents; Psoriasis | 2001 |
Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone.
Topics: Acitretin; Adult; Aged; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; Middle Aged; Psoriasis; Tretinoin; Ultraviolet Therapy | 1991 |
A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study.
Topics: Acitretin; Adult; Aged; Female; Humans; Male; Middle Aged; Psoriasis; Tretinoin | 1991 |
Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study.
Topics: Acitretin; Adolescent; Adult; Aged; Aspartate Aminotransferases; Cholesterol; Double-Blind Method; Drug Combinations; Drug Synergism; Female; Humans; Male; Methoxsalen; Middle Aged; Placebos; Psoriasis; PUVA Therapy; Radiation Dosage; Time Factors; Tretinoin; Triglycerides | 1991 |
Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis.
Topics: Acitretin; Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Tolerance; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Placebos; Psoriasis; Radiation Dosage; Random Allocation; Time Factors; Tretinoin; Ultraviolet Therapy | 1990 |
Intra-epidermal accumulation of polymorphonuclear leukocytes in persistent palmoplantar pustulosis during treatment with acitretin.
Topics: Acitretin; Adult; Chemotaxis, Leukocyte; Clinical Trials as Topic; Drug Tolerance; Female; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Neutrophils; Psoriasis; Skin Diseases, Vesiculobullous; Tretinoin | 1988 |
Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis.
Topics: Acitretin; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Psoriasis; Tretinoin | 1989 |
Side-effect profile of acitretin therapy in psoriasis.
Topics: Acitretin; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Psoriasis; Time Factors; Tretinoin | 1989 |
Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone.
Topics: Acitretin; Adult; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Psoriasis; Radiotherapy Dosage; Tretinoin; Ultraviolet Therapy | 1989 |
A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis.
Topics: Acitretin; Adult; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Etretinate; Female; Humans; Male; Psoriasis; PUVA Therapy; Random Allocation; Tretinoin | 1989 |
A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis.
Topics: Acitretin; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Psoriasis; Tretinoin | 1989 |
Pustulosis palmo-plantaris. Clinical and histological changes during etretin (acitretin) therapy.
Topics: Acitretin; Adult; Aged; Double-Blind Method; Female; Germany; Humans; Male; Middle Aged; Multicenter Studies as Topic; Psoriasis; Random Allocation; Tretinoin | 1989 |
Acitretin in the treatment of severe psoriasis: a randomized double-blind study comparing acitretin and etretinate.
Topics: Acitretin; Adult; Double-Blind Method; Etretinate; Humans; Male; Middle Aged; Psoriasis; Random Allocation; Tretinoin | 1989 |
Acitretin versus etretinate in severe psoriasis. A double-blind randomized Nordic multicenter study in 168 patients.
Topics: Acitretin; Double-Blind Method; Etretinate; Female; Humans; Male; Multicenter Studies as Topic; Psoriasis; Random Allocation; Tretinoin | 1989 |
A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study.
Topics: Acitretin; Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Etretinate; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Psoriasis; Random Allocation; Tretinoin | 1989 |
Treatment of severe psoriasis with etretin (RO 10-1670).
Topics: Acitretin; Alanine Transaminase; Aspartate Aminotransferases; Cholesterol; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Female; gamma-Glutamyltransferase; Humans; Male; Middle Aged; Psoriasis; Tretinoin; Triglycerides | 1987 |
Etretin therapy for severe psoriasis. Evaluation of initial clinical responses.
Topics: Acitretin; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Etretinate; Female; Follow-Up Studies; Humans; Male; Middle Aged; Psoriasis; Random Allocation; Time Factors; Tretinoin | 1987 |
Single dose pharmacokinetics of etretin and etretinate in psoriatic patients.
Topics: Acitretin; Adult; Aged; Drug Administration Schedule; Etretinate; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Psoriasis; Random Allocation; Tretinoin | 1987 |
Treatment of psoriasis with etretin: a preliminary report.
Topics: Acitretin; Adult; Aged; Alopecia; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Psoriasis; Random Allocation; Tretinoin | 1987 |
Acitretin improves psoriasis in a dose-dependent fashion.
Topics: Acitretin; Adult; Cheilitis; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Psoriasis; Tretinoin | 1988 |
Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study.
Topics: Acitretin; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Etretinate; Female; Humans; Male; Middle Aged; Psoriasis; Random Allocation; Tretinoin | 1988 |
Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis.
Topics: Acitretin; Adult; Clinical Trials as Topic; Double-Blind Method; Etretinate; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Psoriasis; PUVA Therapy; Random Allocation; Remission Induction; Tretinoin | 1988 |
Acitretin (Ro 10-1670) in the treatment of severe psoriasis. A randomized double-blind parallel study comparing acitretin and etretinate.
Topics: Acitretin; Adult; Aged; Double-Blind Method; Etretinate; Female; Humans; Male; Middle Aged; Psoriasis; Time Factors; Tretinoin | 1988 |
[Etretinate: pro and con. Risk-benefit analysis of systemic retinoid therapy in psoriasis and recent developments: free aromatic acid, arotinoids].
Topics: Abnormalities, Drug-Induced; Acitretin; Benzoates; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Etretinate; Humans; Lipids; Long-Term Care; Prognosis; Psoriasis; Retinoids; Risk; Skin; Tretinoin | 1985 |
280 other study(ies) available for acitretin and Palmoplantaris Pustulosis
| Article | Year |
|---|---|
Epidemiology and clinical features of pustular psoriasis: A 15-year retrospective cohort.
Topics: Acitretin; Adult; Dermatologic Agents; Female; Humans; Middle Aged; Pregnancy; Psoriasis; Retrospective Studies; Skin Diseases, Vesiculobullous; Young Adult | 2021 |
Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma.
Topics: Acitretin; Adenocarcinoma; Aged; Esophageal Neoplasms; Female; Humans; Middle Aged; Nivolumab; Psoriasis | 2022 |
Segmental vitiligo following acitretin treatment for infantile generalized pustular psoriasis resulting in repigmentation under secukinumab therapy.
Topics: Acitretin; Antibodies, Monoclonal, Humanized; Humans; Psoriasis; Vitiligo | 2022 |
CITY-PSO: Prescribing behaviour of French private-practice dermatologists in psoriasis management: An observational, multicentre, cross-sectional study.
Topics: Acitretin; Adult; Aged; Arthritis, Psoriatic; Cross-Sectional Studies; Dermatologists; Humans; Middle Aged; Psoriasis; Severity of Illness Index | 2022 |
Anti-IL23for nail psoriasis in real life: Results of efficacy and safety during a 52-week period.
Topics: Acitretin; Humans; Methotrexate; Nail Diseases; Psoriasis; Quality of Life; Treatment Outcome | 2022 |
Combined acitretin-methotrexate therapy seems safe and efficient in children with psoriasis.
Topics: Acitretin; Child; Dermatologic Agents; Drug Therapy, Combination; Humans; Keratolytic Agents; Methotrexate; Psoriasis; Treatment Outcome | 2022 |
Demographic aspects, clinical characteristics, and therapeutic approaches in geriatric psoriasis: A study from a tertiary center.
Topics: Acitretin; Aged; Arthritis, Psoriatic; Cross-Sectional Studies; Demography; Female; Humans; Male; Middle Aged; Psoriasis | 2022 |
Successful treatment of a child's pityriasis rubra pilaris (PRP) with ustekinumab and acitretin.
Topics: Acitretin; Adult; Child; Child, Preschool; Female; Humans; Pityriasis Rubra Pilaris; Psoriasis; Ustekinumab | 2022 |
Pediatric Verrucous Psoriasis: A Case Report in a Pediatric Patient and Discussion of the Literature.
Topics: Acitretin; Adalimumab; Adolescent; Child; Dermatologic Agents; Humans; Male; Psoriasis | 2022 |
Real-world data on the use of secukinumab and acitretin in pediatric generalized pustular psoriasis.
Topics: Acitretin; Acute Disease; Antibodies, Monoclonal, Humanized; Blister; Child; Chronic Disease; Humans; Psoriasis; Skin Diseases, Vesiculobullous | 2023 |
Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real-life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists.
Topics: Acitretin; Adalimumab; Biological Products; Child; Dermatologic Agents; Dermatologists; Etanercept; Humans; Methotrexate; Psoriasis; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2022 |
Topics: Acitretin; Alleles; Genetic Predisposition to Disease; HLA-C Antigens; HLA-DQ alpha-Chains; HLA-DQ beta-Chains; Humans; Psoriasis | 2022 |
Different Clinical Features of Pediatric Generalized Pustular Psoriasis in Patients with or without IL36RN Variants.
Topics: Acitretin; Acute Disease; Chronic Disease; Humans; Interleukins; Psoriasis; Skin Diseases, Vesiculobullous; Treatment Outcome | 2023 |
Conventional therapy in psoriasis. Lost in translation?
Topics: Acitretin; Cohort Studies; Cyclosporine; Fumarates; Humans; Methotrexate; Psoriasis | 2023 |
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
Topics: Acitretin; Adjuvants, Immunologic; Biological Factors; Cohort Studies; Cyclosporine; Dermatologic Agents; Fumarates; Humans; Immunologic Factors; Male; Methotrexate; Prospective Studies; Psoriasis; Treatment Outcome | 2023 |
Incidence and Prognosis of COVID-19 in Patients with Psoriasis: A Multicenter Prospective Study from the Eastern Black Sea Region of Turkey.
Topics: Acitretin; Black Sea; COVID-19; Hospitalization; Humans; Incidence; Prognosis; Prospective Studies; Psoriasis; Turkey | 2022 |
Risk of Psychiatric Disorders in Patients with Psoriasis Prescribed Acitretin versus Disease-Modifying Antirheumatic Drugs: A Nationwide Matched Cohort Study.
Topics: Acitretin; Adult; Antirheumatic Agents; Cohort Studies; Female; Humans; Mental Disorders; Psoriasis; Risk Factors | 2023 |
A case of successful treatment of concurrent verrucous epidermal naevi and psoriasis with apremilast.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Humans; Nevus, Sebaceous of Jadassohn; Psoriasis; Severity of Illness Index; Skin Neoplasms; Treatment Outcome | 2023 |
The real-world effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for treating moderate-to-severe psoriasis.
Topics: Acitretin; Cohort Studies; Cyclosporine; Fumarates; Humans; Methotrexate; Psoriasis | 2023 |
Role and mechanism of matrine alone and combined with acitretin for HaCaT cells and psoriasis-like murine models.
Topics: Acitretin; Alkaloids; Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Humans; Matrines; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Psoriasis; Quinolizines; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments.
Topics: Acitretin; Adalimumab; Adult; Anti-Inflammatory Agents; Cyclosporine; Cytokine TWEAK; Dermatologic Agents; Etanercept; Female; Humans; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2020 |
Synthesis and in vitro cytotoxicity evaluation of star-shaped polymethacrylic conjugates with methotrexate or acitretin as potential antipsoriatic prodrugs.
Topics: Acitretin; Apoptosis; Cell Cycle; Cell Line, Tumor; Chemistry Techniques, Synthetic; Dose-Response Relationship, Drug; Humans; Methotrexate; Polymethacrylic Acids; Psoriasis; Skin | 2020 |
Acitretin inhibits IL-17A-induced IL-36 expression in keratinocytes by down-regulating IκBζ.
Topics: Acitretin; Animals; Anti-Inflammatory Agents; Cell Line; Disease Models, Animal; Down-Regulation; Female; Humans; I-kappa B Kinase; Imiquimod; Interleukin-1; Interleukin-17; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis | 2020 |
Verrucous psoriasis treated with methotrexate and acitretin combination therapy.
Topics: Acitretin; Aged; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Keratolytic Agents; Methotrexate; Psoriasis | 2019 |
Plasma retinol as a predictive biomarker of disease activity and response to acitretin monotherapy in children with generalized pustular psoriasis.
Topics: Acitretin; Biomarkers; Child; Humans; Keratolytic Agents; Psoriasis; Vitamin A | 2020 |
Real-world trends in biologic, oral systemic, and phototherapy in US patients with psoriasis or psoriatic arthritis.
Topics: Acitretin; Adalimumab; Administration, Oral; Adult; Arthritis, Psoriatic; Biological Products; Dermatologic Agents; Drug Utilization; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Phototherapy; Psoriasis; Ustekinumab | 2020 |
[Acute pancreatitis under acitretin].
Topics: Acitretin; Adult; Humans; Male; Pancreatitis; Psoriasis | 2020 |
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
Topics: Acitretin; Cyclosporine; Drug Monitoring; Humans; Methotrexate; Piperidines; Psoriasis; Pyrimidines; Thalidomide | 2020 |
Combination therapy with acitretin and glycyrrhizin in generalized pustular psoriasis with liver test abnormalities: A case series.
Topics: Acitretin; Glycyrrhizic Acid; Humans; Keratolytic Agents; Liver; Psoriasis | 2020 |
The adverse effect profile of acitretin in a pediatric dermatology population-Longitudinal cohort study and recommendations for monitoring.
Topics: Acitretin; Adolescent; Child; Child, Preschool; Dermatology; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Ichthyosis; Infant; Infant, Newborn; Keratolytic Agents; Longitudinal Studies; Male; Practice Guidelines as Topic; Psoriasis; Retrospective Studies | 2020 |
When the old works better than the new: A case of severe nail psoriasis successfully treated with acitretin after failure of two biologic regimens.
Topics: Acitretin; Biological Products; Humans; Keratolytic Agents; Nail Diseases; Psoriasis | 2020 |
Optimizing acitretin administration by means of a novel method of dose estimation, capsule preservation, and medium for suspension.
Topics: Acitretin; Humans; Keratolytic Agents; Psoriasis; Research Design | 2020 |
Planifier une grossesse chez une patiente avec un psoriasis.
Topics: Acitretin; Contraindications, Drug; Dermatologic Agents; Female; Fertility; Humans; Male; Methotrexate; Patient Care Planning; Preconception Care; Pregnancy; Pregnancy Complications; Psoriasis | 2020 |
Le choix thérapeutique : médicaments du psoriasis et grossesse avant, pendant et après la grossesse.
Topics: Acitretin; Biological Factors; Breast Feeding; Contraindications, Drug; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Methotrexate; Pregnancy; Pregnancy Complications; Pregnancy Complications, Infectious; Psoriasis; Risk Factors; Ultraviolet Therapy | 2020 |
Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.
Topics: Acitretin; Aged; Biological Products; Dermatologic Agents; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; Glucocorticoids; Humans; Immune Checkpoint Inhibitors; Male; Methotrexate; Middle Aged; Neoplasms; Psoriasis; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2021 |
Secukinumab and acitretin as a combination therapy for three clinical forms of severe psoriasis in multi-drug refractory patients: A case series of high efficacy and safety profile.
Topics: Acitretin; Antibodies, Monoclonal, Humanized; Humans; Pharmaceutical Preparations; Psoriasis; Treatment Outcome | 2021 |
Drug survival and safety profile of acitretin monotherapy in patients with psoriasis: A multicenter retrospective study.
Topics: Acitretin; Cheilitis; Female; Humans; Male; Pharmaceutical Preparations; Psoriasis; Retrospective Studies | 2021 |
Successful treatment of paediatric generalized pustular psoriasis with secukinumab: a case series.
Topics: Acitretin; Acute Disease; Antibodies, Monoclonal, Humanized; Child; Chronic Disease; Exanthema; Humans; Psoriasis; Skin Diseases, Vesiculobullous | 2022 |
The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study.
Topics: Acitretin; Adult; Aged; Anti-Inflammatory Agents; Cardiovascular Diseases; Cyclosporine; Female; Humans; Incidence; Male; Methotrexate; Middle Aged; Phototherapy; Proportional Hazards Models; Psoriasis; Republic of Korea; Severity of Illness Index; Young Adult | 2021 |
Circulating microRNA profile unveils mechanisms of action of acitretin for psoriasis vulgaris.
Topics: Acitretin; Adult; Area Under Curve; Circulating MicroRNA; Down-Regulation; Female; Gene Expression Profiling; HaCaT Cells; Humans; Male; Psoriasis; Reproducibility of Results; ROC Curve; Signal Transduction | 2021 |
Psoriasis: a brief overview.
Topics: Acitretin; Humans; Immunosuppressive Agents; Methotrexate; Phototherapy; Psoriasis | 2021 |
Clinical analysis of generalized pustular psoriasis in Chinese patients: A retrospective study of 110 patients.
Topics: Acitretin; Acute Disease; China; Female; Humans; Male; Middle Aged; Psoriasis; Retrospective Studies | 2021 |
Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy.
Topics: Acitretin; Cohort Studies; Drug Therapy, Combination; Humans; Liver Cirrhosis; Methotrexate; Psoriasis; Retrospective Studies; Risk Factors | 2021 |
A case of psoriasis successfully treated by extracorporeal photopheresis during COVID-19 pandemic.
Topics: Acitretin; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Contraindications, Drug; COVID-19; Cyclosporine; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Nails; Pandemics; Photopheresis; Psoriasis; Quality of Life; SARS-CoV-2; Severity of Illness Index; Ultraviolet Therapy | 2021 |
IL-22 Downregulates Peptidylarginine Deiminase-1 in Human Keratinocytes: Adding Another Piece to the IL-22 Puzzle in Epidermal Barrier Formation.
Topics: Acitretin; Biopsy; Cell Differentiation; Cell Line; Citrullination; Dermatitis, Atopic; Down-Regulation; Epidermis; Filaggrin Proteins; Humans; Interleukin-22; Interleukins; Keratin-1; Keratinocytes; Primary Cell Culture; Protein-Arginine Deiminase Type 1; Psoriasis; Vitamin D | 2022 |
Nivolumab Induced Psoriasis Successfully Treated With Acitretin.
Topics: Acitretin; Humans; Immunotherapy; Nivolumab; Programmed Cell Death 1 Receptor; Psoriasis | 2021 |
Management of patients with psoriasis.
Topics: Acitretin; Administration, Cutaneous; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cyclosporine; Dermatologic Agents; Disease Management; Emollients; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Phototherapy; Psoriasis; Thalidomide | 2017 |
The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis.
Topics: Acitretin; Animals; Cells, Cultured; Dermatologic Agents; Drug Therapy, Combination; Humans; Keratolytic Agents; Liver; Liver Cirrhosis; Male; Methotrexate; Mice; Psoriasis; Skin | 2017 |
Palmoplantar pustulosis - a cross-sectional analysis in Germany.
Topics: Acitretin; Adrenal Cortex Hormones; Adult; Age of Onset; Arthritis, Psoriatic; Body Mass Index; Comorbidity; Cross-Sectional Studies; Dermatologic Agents; Female; Germany; Humans; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; Quality of Life; Severity of Illness Index; Smoking; Ultraviolet Therapy; Young Adult | 2017 |
Psoriasis in solid organ transplant patients: best practice recommendations from The Medical Board of the National Psoriasis Foundation.
Topics: Acitretin; Adult; Algorithms; Databases, Factual; Female; Humans; Male; Organ Transplantation; Psoriasis; Ultraviolet Therapy; Ustekinumab | 2018 |
Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
Topics: Acitretin; Adalimumab; Austria; Biological Products; Combined Modality Therapy; Cyclosporine; Czech Republic; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Fumarates; Humans; Infliximab; Israel; Italy; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Netherlands; Psoriasis; PUVA Therapy; Registries; Severity of Illness Index; Ustekinumab | 2018 |
[Still too many pregnancies with Soriatane
Topics: Abortion, Induced; Acitretin; Adult; Evidence-Based Medicine; Female; France; Humans; Keratolytic Agents; Pregnancy; Pregnancy Complications; Psoriasis; Teratogens | 2017 |
Angioedema without urticaria caused by oral acitretin.
Topics: Acitretin; Angioedema; Female; Humans; Keratolytic Agents; Middle Aged; Psoriasis | 2017 |
Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod- induced Psoriatic Mouse Model.
Topics: Acitretin; Angiogenesis Inhibitors; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Female; Imiquimod; Mice, Inbred BALB C; Microvessels; Neovascularization, Pathologic; Psoriasis; Signal Transduction; Skin; Thalidomide; Vascular Endothelial Growth Factor A | 2018 |
An extemporaneous approach for optimizing acitretin dosing in pediatric patients.
Topics: Acitretin; Capsules; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infant; Pediatrics; Psoriasis; Risk Assessment; Suspensions; Treatment Outcome | 2018 |
Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: ex vivo-in vivo evaluation study.
Topics: Acitretin; Animals; Calorimetry, Differential Scanning; Cell Death; Cell Line; Drug Carriers; Drug Compounding; Drug Stability; Gels; Humans; Kinetics; Liposomes; Male; Mice; Nanoparticles; Particle Size; Psoriasis; Rats; Skin; Skin Absorption; Skin Irritancy Tests; Solubility; Static Electricity; X-Ray Diffraction | 2018 |
Association of IL36RN mutations with clinical features, therapeutic response to acitretin, and frequency of recurrence in patients with generalized pustular psoriasis.
Topics: Acitretin; Adult; Female; Genotype; Humans; Interleukins; Keratolytic Agents; Maintenance Chemotherapy; Male; Mutation; Psoriasis; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2018 |
Acitretin-Altered Squamous Cell Carcinoma: A Pitfall in Diagnosis.
Topics: Acitretin; Aged; Carcinoma, Squamous Cell; Diagnosis, Differential; Female; Humans; Keratolytic Agents; Male; Psoriasis; PUVA Therapy; Skin Neoplasms | 2019 |
Case Report: Successful Treatment of Chromoblastomycosis Caused by
Topics: Acitretin; Adrenal Cortex Hormones; Antifungal Agents; Chromoblastomycosis; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Itraconazole; Male; Middle Aged; Psoriasis; Saccharomycetales; Skin; Treatment Outcome | 2018 |
The polymorphisms of growth factor genes (VEGFA & EGF) were associated with response to acitretin in psoriasis.
Topics: Acitretin; Adult; Calcitriol; China; Drug Administration Schedule; Epidermal Growth Factor; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Psoriasis; Vascular Endothelial Growth Factor A | 2018 |
Erythrodermic psoriasis and human immunodeficiency virus: association and therapeutic challenges.
Topics: Acitretin; Aged; Anti-Retroviral Agents; Dermatitis, Exfoliative; HIV Infections; Humans; Keratolytic Agents; Male; Psoriasis | 2018 |
Hydroxyurea and acitretin as a novel combination therapy in severe plaque psoriasis.
Topics: Acitretin; Administration, Oral; Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Male; Middle Aged; Psoriasis; Severity of Illness Index; Treatment Outcome | 2018 |
Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: A retrospective, comparative cohort study.
Topics: Acitretin; Adalimumab; Adolescent; Adult; Aged; Biological Products; Drug Utilization; Etanercept; Female; Humans; Immunosuppressive Agents; Male; Medication Adherence; Methotrexate; Middle Aged; Propensity Score; Psoriasis; Retrospective Studies; Treatment Outcome; Ustekinumab; Young Adult | 2018 |
Systemic Treatment of Moderate to Severe Psoriasis in Pediatric Patients in Galicia, Spain: A Descriptive Study.
Topics: Acitretin; Adolescent; Child; Comorbidity; Cross-Sectional Studies; Drug Utilization; Humans; Methotrexate; Phototherapy; Procedures and Techniques Utilization; Psoriasis; Spain | 2018 |
Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
Topics: Acitretin; Administration, Cutaneous; Aerosols; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Esters; Female; Fumarates; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Thalidomide; Treatment Outcome | 2019 |
Long-term safety and drug survival of acitretin in psoriasis: a retrospective observational study.
Topics: Acitretin; Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis; Retrospective Studies; Time Factors; Treatment Outcome | 2019 |
Ocular findings in patients with psoriasis: is it related to the side effects of treatment or to psoriasis itself? A case-control study.
Topics: Acitretin; Adult; Case-Control Studies; Dermatologic Agents; Dry Eye Syndromes; Female; Humans; Logistic Models; Male; Methotrexate; Middle Aged; Odds Ratio; Prospective Studies; Psoriasis; Young Adult | 2020 |
Low dose acitretin versus methotrexate in the treatment of palmoplantar psoriasis: a case series.
Topics: Acitretin; Aged; Dermatologic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Methotrexate; Middle Aged; Psoriasis | 2019 |
Acitretin-induced curling of hair in a Korean male.
Topics: Acitretin; Administration, Oral; Asian People; Drug Substitution; Hair; Humans; Keratolytic Agents; Male; Methotrexate; Middle Aged; Nail Diseases; Psoriasis; Republic of Korea; Treatment Outcome | 2019 |
Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study.
Topics: Acitretin; Adalimumab; Adolescent; Adult; Age of Onset; Biological Products; Cyclosporine; Dermatologic Agents; Etanercept; Female; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Prospective Studies; Psoriasis; Spain; Ustekinumab | 2020 |
Lp-PLA2 as a promising predictor of comorbidities in patients with severe psoriasis.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acitretin; Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Female; Humans; Keratolytic Agents; Male; Methotrexate; Middle Aged; Obesity; Psoriasis; Risk Factors; Young Adult | 2020 |
Severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome caused by de novo mutation in the DSP gene misdiagnosed as generalized pustular psoriasis and treatment of acitretin with gabapentin.
Topics: Acitretin; Administration, Cutaneous; Administration, Oral; Child, Preschool; Dermatitis, Exfoliative; Desmoplakins; Diagnosis, Differential; Diagnostic Errors; DNA Mutational Analysis; Female; Gabapentin; Humans; Hypersensitivity; Mutation, Missense; Psoriasis; Severity of Illness Index; Skin; Syndrome; Tacrolimus; Treatment Outcome; Wasting Syndrome | 2019 |
Adipocyte Fatty Acid-Binding Protein as a Novel Marker of Psoriasis and Clinical Response to Acitretin.
Topics: Acitretin; Adipocytes; Adult; Biomarkers; Body Mass Index; Fatty Acid-Binding Proteins; Female; Humans; Inflammation; Male; Middle Aged; Psoriasis; Risk Factors; Severity of Illness Index | 2019 |
Cytotoxic and genotoxic effects of acitretin, alone or in combination with psoralen-ultraviolet A or narrow-band ultraviolet B-therapy in psoriatic patients.
Topics: Acitretin; Apoptosis; Cell Division; Combined Modality Therapy; Comet Assay; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Keratolytic Agents; Lymphocytes; Male; Methoxsalen; Micronucleus Tests; Middle Aged; Necrosis; Psoriasis; PUVA Therapy; Radiation-Sensitizing Agents; Ultraviolet Rays | 2013 |
Nail psoriasis masqueraded by secondary infection with Rhodotorula mucilaginosa.
Topics: Acitretin; Adult; Anti-Inflammatory Agents; Antifungal Agents; Betamethasone; Calcitriol; Coinfection; Dermatologic Agents; Humans; Itraconazole; Keratolytic Agents; Male; Microbiological Techniques; Molecular Diagnostic Techniques; Nails; Onychomycosis; Psoriasis; Rhodotorula; Treatment Outcome | 2013 |
Liraglutide in combination with acitretin for severe recalcitrant psoriasis.
Topics: Acitretin; Chronic Disease; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Incretins; Keratolytic Agents; Liraglutide; Male; Middle Aged; Psoriasis | 2013 |
Acitretin prescribing patterns in women of childbearing potential.
Topics: Acitretin; Adult; Age Factors; Aged; Databases, Factual; Etretinate; Female; Health Care Surveys; Humans; Keratolytic Agents; Male; Middle Aged; Practice Patterns, Physicians'; Psoriasis; Severity of Illness Index; United States | 2013 |
Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
Topics: Abnormalities, Drug-Induced; Acitretin; Biotransformation; Cardiovascular Diseases; Comorbidity; Contraindications; Drug Administration Schedule; Drug Interactions; Female; Gene Expression Regulation; Humans; Immunosuppressive Agents; Keratinocytes; Metabolic Syndrome; Pregnancy; Pregnancy Complications; Psoriasis; Receptors, Retinoic Acid; Risk Assessment; Tetracyclines | 2013 |
Demodicidosis associated with psoriasis therapy--two case reports.
Topics: Acitretin; Aged; Animals; Anti-Inflammatory Agents; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Middle Aged; Mite Infestations; Mites; Psoriasis; PUVA Therapy; Steroids; Tacrolimus | 2013 |
Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
Topics: Acitretin; Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Factors; Combined Modality Therapy; Dermatologic Agents; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Nail Diseases; Nails; Onycholysis; Phototherapy; Psoriasis; Receptors, Tumor Necrosis Factor | 2013 |
Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
Topics: Acitretin; Adult; Age Factors; Arthritis, Psoriatic; Biological Factors; Child; Clinical Trials as Topic; Combined Modality Therapy; Cost-Benefit Analysis; Drug Substitution; Evidence-Based Medicine; Female; Humans; Immunosuppressive Agents; Male; Meta-Analysis as Topic; Multicenter Studies as Topic; Photochemotherapy; Pregnancy; Pregnancy Complications; Psoriasis; Severity of Illness Index; Sex Factors; Spain; Treatment Failure; Treatment Outcome | 2013 |
Complete and rapid regression of primary cutaneous follicular lymphoma with repeated oral administration of acitretin for palmoplantar psoriasis.
Topics: Acitretin; Administration, Oral; Follow-Up Studies; Humans; Keratolytic Agents; Lymphoma, Follicular; Male; Middle Aged; Psoriasis; Scalp Dermatoses; Severity of Illness Index; Skin Neoplasms; Treatment Outcome | 2013 |
Lichen planus mimicking recalcitrant ulcerative psoriasis: when is it time to biopsy?
Topics: Acitretin; Adult; Biopsy; Clobetasol; Dermatologic Agents; Female; Humans; Hydroxychloroquine; Lichen Planus; Psoriasis; Treatment Outcome | 2013 |
Elephantasis nostras verrucosa and psoriasis: only a coincidence?
Topics: Acitretin; Chlorhexidine; Disinfectants; Diuretics; Elephantiasis; Furosemide; Humans; Keratolytic Agents; Keratosis; Lower Extremity; Male; Middle Aged; Papilloma; Psoriasis; Stockings, Compression; Treatment Outcome | 2013 |
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
Topics: Acitretin; Adalimumab; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Cyclosporine; Etanercept; Female; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Prospective Studies; Psoriasis; Receptors, Tumor Necrosis Factor; Registries; Risk Assessment; Spain; Ustekinumab | 2015 |
Hypertriglyceridaemia with acitretin use: a proposal for its management in the context of overall cardiovascular risk.
Topics: Acitretin; Cardiovascular Diseases; Humans; Hypertriglyceridemia; Keratolytic Agents; Psoriasis; Retrospective Studies; Risk Assessment; Risk Reduction Behavior | 2014 |
Unusual presentation of inflammatory linear verrucous epidermal naevus mimicking linear psoriasis successfully treated with oral retinoid.
Topics: Acitretin; Adult; Diagnosis, Differential; Diagnostic Errors; Female; Humans; Keratolytic Agents; Nevus, Sebaceous of Jadassohn; Psoriasis | 2015 |
Frequency of monoclonal gammopathy in psoriatic patients receiving anti-TNF therapy compared with patients taking conventional drugs: a cross-sectional study.
Topics: Acitretin; Adalimumab; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; Cyclosporine; Etanercept; Female; Humans; Immunosuppressive Agents; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Prevalence; Psoriasis; Tumor Necrosis Factor-alpha | 2015 |
Low-dose acitretin in treatment of plaque-type psoriasis: descriptive study of efficacy and safety.
Topics: Acitretin; Adult; Aged; Aged, 80 and over; Female; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome | 2015 |
Effect of pharmacological intervention on MIP-1α, MIP-1β and MCP-1 expression in patients with psoriasis vulgaris.
Topics: Acitretin; Adult; Case-Control Studies; Chemokine CCL2; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunosuppressive Agents; Keratolytic Agents; Macrophage Inflammatory Proteins; Male; Middle Aged; Psoriasis; Tacrolimus; Young Adult | 2014 |
Acquired ichthyosis during acitretin therapy for psoriasis vulgaris.
Topics: Acitretin; Aged; Cyclosporine; Dermatologic Agents; Female; Humans; Ichthyosis; Keratolytic Agents; Psoriasis | 2016 |
Acitretin-induced alopecia areata: a case report.
Topics: Acitretin; Adult; Alopecia Areata; Female; Humans; Keratolytic Agents; Psoriasis | 2015 |
Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.
Topics: Acitretin; Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cross-Sectional Studies; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Young Adult | 2014 |
A comparative study of histopathological findings in skin biopsies from patients with psoriasis before and after treatment with acitretin, methotrexate and phototherapy.
Topics: Acitretin; Adult; Biopsy; Female; Humans; Male; Methotrexate; Phototherapy; Psoriasis; Severity of Illness Index; Skin; Treatment Outcome | 2015 |
The 'switcher' patient profile in psoriasis treatment: from traditional to biological and from biological to traditional systemic drugs.
Topics: Acitretin; Adalimumab; Adult; Aged; Biological Factors; Cyclosporine; Dermatologic Agents; Drug Substitution; Etanercept; Female; Humans; Infliximab; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Psoriasis; Ustekinumab; Young Adult | 2015 |
How are we using systemic drugs to treat psoriasis in children? An insight into current clinical U.K. practice.
Topics: Acitretin; Adolescent; Child; Child, Preschool; Cyclosporine; Dapsone; Dermatologic Agents; Fumarates; Humans; Immunosuppressive Agents; Methotrexate; Practice Patterns, Physicians'; Psoriasis; United Kingdom | 2015 |
Systemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: report on 17 cases.
Topics: Acitretin; Adult; Aged; Anti-Inflammatory Agents; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Fumarates; Germany; Humans; Infliximab; Isoxazoles; Keratolytic Agents; Leflunomide; Male; Methotrexate; Middle Aged; Prednisolone; Psoriasis; Retrospective Studies | 2015 |
Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis.
Topics: Acitretin; Administration, Oral; Adult; Age Factors; Aged; Arthritis, Psoriatic; Databases, Factual; Dermatologic Agents; Drug Prescriptions; Female; Folic Acid; Humans; Israel; Kaplan-Meier Estimate; Keratolytic Agents; Male; Medication Adherence; Metabolic Syndrome; Methotrexate; Middle Aged; Psoriasis | 2015 |
Thrombocytopenia probably induced by acitretin.
Topics: Acitretin; Adrenal Cortex Hormones; Aged; Dermatologic Agents; Drug Substitution; Hand Dermatoses; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Methylprednisolone; Psoriasis; Thrombocytopenia | 2015 |
VDR gene polymorphisms are associated with the clinical response to calcipotriol in psoriatic patients.
Topics: Acitretin; Adult; Calcitriol; Calcium; Dermatologic Agents; Drug Therapy, Combination; Female; Genotype; Humans; Keratolytic Agents; Male; Middle Aged; Ointments; Polymorphism, Single Nucleotide; Psoriasis; Receptors, Calcitriol; Severity of Illness Index | 2015 |
Essential Truths for the Care and Management of Moderate-to-Severe Psoriasis.
Topics: Acitretin; Adalimumab; Attitude of Health Personnel; Biological Products; Cyclosporine; Dermatologic Agents; Etanercept; Humans; Infliximab; Methotrexate; Perception; Practice Patterns, Physicians'; Psoriasis | 2015 |
Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Topics: Acitretin; Adalimumab; Adolescent; Adult; Aged; Antibodies, Monoclonal; Biological Products; Certolizumab Pegol; Cyclosporine; Dermatologic Agents; Drug Prescriptions; Drug Therapy, Combination; Etanercept; Female; Humans; Infliximab; Male; Methotrexate; Middle Aged; Practice Patterns, Physicians'; Psoriasis; Retrospective Studies; Severity of Illness Index; Ultraviolet Therapy; Ustekinumab; Young Adult | 2015 |
Acitretin-induced spiny follicular hyperkeratosis.
Topics: Acitretin; Female; Humans; Keratolytic Agents; Keratosis; Middle Aged; Psoriasis | 2016 |
Successful treatment of palmoplantar pustulosis with isotretinoin.
Topics: Acitretin; Anti-Inflammatory Agents; Biopsy; Calcitriol; Ceramides; Cholesterol; Clobetasol; Combined Modality Therapy; Diagnostic Errors; Drug Combinations; Drug Substitution; Eczema; Emollients; Fatty Acids; Female; Humans; Isotretinoin; Male; Middle Aged; Psoriasis; Ultraviolet Therapy | 2015 |
European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.
Topics: Acitretin; Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Drug Therapy, Combination; Etanercept; Fumarates; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Psoriasis; Ustekinumab | 2015 |
Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
Topics: Acitretin; Adolescent; Adult; Aged; Algorithms; Cyclosporine; Dermatologic Agents; Female; Humans; Male; Methotrexate; Middle Aged; Psoriasis; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2016 |
Systemic treatments in childhood psoriasis: a French multicentre study on 154 children.
Topics: Acitretin; Adolescent; Child; Child, Preschool; Cyclosporine; Dermatologic Agents; France; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Phototherapy; Psoriasis; Treatment Outcome | 2016 |
Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: A single-center, Italian study.
Topics: Acitretin; Adult; Cyclosporine; Dermatologic Agents; Female; Humans; Italy; Male; Methotrexate; Middle Aged; Phototherapy; Psoriasis; Retrospective Studies; Treatment Outcome | 2016 |
Lornoxicam-induced acute generalized exanthematous pustulosis.
Topics: Acitretin; Acute Disease; Acute Generalized Exanthematous Pustulosis; Adult; Biopsy, Needle; Female; Follow-Up Studies; Humans; Immunohistochemistry; Low Back Pain; Piroxicam; Psoriasis; Risk Assessment; Withholding Treatment | 2016 |
[Cost Effectiveness of Treatments of Psoriasis with a PASI 75 and one Period of 12 Weeks].
Topics: Acitretin; Adalimumab; Cost-Benefit Analysis; Cyclosporine; Etanercept; Health Care Costs; Humans; Immunosuppressive Agents; Infliximab; Methotrexate; Models, Economic; Psoriasis; PUVA Therapy; Severity of Illness Index; Spain; Time Factors; Treatment Outcome; Ultraviolet Therapy; Ustekinumab | 2016 |
Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.
Topics: Acitretin; Adult; Consolidation Chemotherapy; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Interleukin-12; Interleukin-23; Interleukins; Keratolytic Agents; Middle Aged; Mutation; Psoriasis; Remission Induction; Ustekinumab | 2016 |
Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris.
Topics: Acitretin; Biological Factors; Cyclosporine; Dermatology; Fumarates; Glucocorticoids; Humans; Immunosuppressive Agents; Psoriasis; Societies, Medical; Switzerland; Thalidomide | 2016 |
Generalized pustular psoriasis treated with ustekinumab.
Topics: Acitretin; Adalimumab; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Cyclosporine; Drug Resistance; Female; Humans; Immunosuppressive Agents; Keratolytic Agents; Methotrexate; Psoriasis; Skin Diseases, Vesiculobullous; Treatment Outcome; Ustekinumab | 2016 |
Acitretin and aloe-emodin loaded chitin nanogel for the treatment of psoriasis.
Topics: Acitretin; Animals; Anthraquinones; Chitin; Drug Carriers; Mice; Microscopy, Electron, Scanning; Nanostructures; Psoriasis; Spectroscopy, Fourier Transform Infrared; Swine; Thermogravimetry; X-Ray Diffraction | 2016 |
Effectiveness and Safety of Acitretin in Children with Plaque Psoriasis: A Multicenter Retrospective Analysis.
Topics: Acitretin; Adolescent; Age Factors; Child; Child, Preschool; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Keratolytic Agents; Male; Patient Safety; Psoriasis; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2016 |
Small Molecules for Psoriasis.
Topics: Acitretin; Administration, Oral; Dermatologic Agents; Evidence-Based Medicine; Humans; Piperidines; Psoriasis; PUVA Therapy; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
[Effect of acitretin and methotrexate on treatment of
severe plaque psoriasis].
Topics: Acitretin; Humans; Methotrexate; Psoriasis | 2016 |
Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: A multicenter, cohort study.
Topics: Acitretin; Adolescent; Child; Cohort Studies; Cyclosporine; Dermatologic Agents; Female; Humans; Male; Methotrexate; Psoriasis; Treatment Outcome | 2017 |
Annular pustular psoriasis in a 14-month-old girl: a therapeutic challenge.
Topics: Acitretin; Administration, Oral; Administration, Topical; Female; Humans; Infant; Keratolytic Agents; Prednisolone; Psoriasis; Severity of Illness Index; Skin; Treatment Outcome | 2017 |
Optimizing acitretin use in patients with plaque psoriasis.
Topics: Acitretin; Drug Dosage Calculations; Humans; Keratolytic Agents; Psoriasis; Remission Induction; Retrospective Studies; Skin; Time Factors; Treatment Outcome | 2017 |
Biologic drug survival in Israeli psoriasis patients.
Topics: Acitretin; Adalimumab; Adult; Databases, Factual; Dermatologic Agents; Drug Substitution; Drug Therapy, Combination; Drug Tolerance; Etanercept; Female; Humans; Immunosuppressive Agents; Infliximab; Interleukin-12 Receptor beta 1 Subunit; Israel; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Psoriasis; Time Factors; Tumor Necrosis Factor-alpha; Ustekinumab | 2017 |
Clinical profiles of pediatric patients with GPP alone and with different IL36RN genotypes.
Topics: Acitretin; Adolescent; Asian People; Child; Child, Preschool; Epigenesis, Genetic; Female; Genetic Predisposition to Disease; Genotype; Heterozygote; Homozygote; Humans; Interleukins; Keratolytic Agents; Male; Mutation; Prospective Studies; Psoriasis; Recurrence; Retrospective Studies; Suppuration; Withholding Treatment | 2017 |
Recalcitrant infantile generalized pustular psoriasis successfully treated with acitretin and narrowband ultraviolet B.
Topics: Acitretin; Drug Resistance; Humans; Immunosuppressive Agents; Infant; Keratolytic Agents; Male; Psoriasis; Skin; Treatment Outcome; Ultraviolet Therapy | 2018 |
Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries.
Topics: Acitretin; Adult; Biological Products; Body Mass Index; Comorbidity; Coronary Disease; Cyclosporine; Czech Republic; Dermatologic Agents; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Hypertension; Keratolytic Agents; Male; Methotrexate; Middle Aged; Obesity; Phototherapy; Prevalence; Psoriasis; Quality of Life; Registries; Retreatment; Retrospective Studies; Risk Factors; Severity of Illness Index | 2017 |
Juvenile generalized pustular psoriasis is a chronic recalcitrant disease: an analysis of 27 patients seen in a tertiary hospital in Johor, Malaysia.
Topics: Acitretin; Acute Disease; Adolescent; Adult; Age of Onset; CARD Signaling Adaptor Proteins; Child; Child, Preschool; Chronic Disease; Cyclosporine; Dermatologic Agents; Female; Guanylate Cyclase; Humans; Interleukins; Keratolytic Agents; Malaysia; Male; Membrane Proteins; Pregnancy; Pregnancy Complications; Psoriasis; Respiratory Tract Infections; Retrospective Studies; Risk Factors; Severity of Illness Index; Steroids; Stress, Psychological; Tertiary Care Centers; Vaccination; Young Adult | 2017 |
[Clinical analysis of 82 cases of generalized pustular psoriasis].
Topics: Acitretin; Adrenal Cortex Hormones; Adult; Age of Onset; Child; Disease Progression; Female; Hospitalization; Humans; Length of Stay; Male; Prognosis; Psoriasis; Retrospective Studies | 2017 |
Cushing's Syndrome Induced by High-Potency Topical Corticosteroids in Two Children with Palmoplantar Psoriasis Taking Acitretin.
Topics: Acitretin; Child; Cushing Syndrome; Dermatologic Agents; Glucocorticoids; Humans; Psoriasis | 2017 |
Treating acute onset of psoriasis.
Topics: Acitretin; Acute Disease; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Body Surface Area; Calcitriol; Dermatologic Agents; Diagnosis, Differential; Drug Monitoring; Female; Humans; Immunosuppressive Agents; Keratolytic Agents; Middle Aged; Nurse Practitioners; Nursing Assessment; Patient Education as Topic; Phototherapy; Physical Examination; Primary Health Care; Psoriasis; Tacrolimus | 2008 |
Acitretin is a safe treatment option for infantile pustular psoriasis.
Topics: Acitretin; Administration, Oral; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Infant; Keratolytic Agents; Prednisolone; Psoriasis; Treatment Outcome | 2008 |
Evaluation of the transfusion safety of blood products and determination of plasma concentrations of acitretin and etretinate in patients receiving transfusions.
Topics: Acitretin; Adolescent; Adult; Aged; Biological Products; Blood Donors; Blood Transfusion; Chromatography, High Pressure Liquid; Drug Contamination; Etretinate; Female; Half-Life; Humans; Male; Middle Aged; Psoriasis; Teratogens; Transfusion Reaction | 2008 |
Home narrowband UV-B phototherapy in combination with low-dose acitretin in patients with moderate to severe psoriasis.
Topics: Acitretin; Dose-Response Relationship, Drug; Home Care Services; Humans; Keratolytic Agents; Patient Satisfaction; Psoriasis; Quality of Life; Severity of Illness Index; Ultraviolet Therapy | 2008 |
Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of psoriatic patients: preliminary study on a possible correlation between generalized immune status, treatments and disease.
Topics: Acitretin; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Case-Control Studies; Cross-Sectional Studies; Cyclosporine; Dermatologic Agents; Female; Gene Frequency; Genotype; Histocompatibility Antigens Class I; HLA Antigens; HLA-G Antigens; Humans; Immune System; Interleukin-10; Male; Middle Aged; Polymorphism, Genetic; Psoriasis; T-Lymphocytes; Young Adult | 2008 |
Steroid swapping between friends: adrenal suppression secondary to psoriasis treatment.
Topics: Acitretin; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Clobetasol; Dermatologic Agents; Friends; Glucocorticoids; Humans; Male; Middle Aged; Prednisone; Prescription Drugs; Psoriasis | 2009 |
ILVEN: is it psoriasis? Debate based on successful treatment with etanercept.
Topics: Acitretin; Adult; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Dose-Response Relationship, Drug; Etanercept; Female; Humans; Immunoglobulin G; Keratolytic Agents; Nevus; Psoriasis; Receptors, Tumor Necrosis Factor; Skin Neoplasms | 2008 |
Fulminant hepatic failure following overdose of the vitamin A metabolite acitretin.
Topics: Acitretin; Adult; Drug Overdose; Female; Humans; Keratolytic Agents; Liver Failure, Acute; Psoriasis; Suicide, Attempted | 2009 |
Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control.
Topics: Acitretin; Adult; Female; Ficusin; Humans; Male; Middle Aged; Photochemotherapy; Psoriasis; Severity of Illness Index; Vascular Endothelial Growth Factor A | 2009 |
Achilles tendon ossification after treatment with acitretin.
Topics: Achilles Tendon; Acitretin; Humans; Keratolytic Agents; Male; Middle Aged; Nail Diseases; Ossification, Heterotopic; Psoriasis | 2010 |
[Two faces of Janus. Coexistence of systemic lupus erythematosus and psoriasis in the same patient].
Topics: Acitretin; Adult; False Negative Reactions; Female; Humans; Immunosuppressive Agents; Keratolytic Agents; Lupus Erythematosus, Systemic; Psoriasis; Thalidomide; Treatment Outcome | 2010 |
Shopping for psoriasis medications on the Internet.
Topics: Acitretin; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Calcitriol; Commerce; Dermatologic Agents; Etanercept; France; Humans; Immunoglobulin G; Internet; Nonprescription Drugs; Psoriasis; Receptors, Tumor Necrosis Factor; Self Medication | 2009 |
Severe nail psoriasis with a rapid response to acitretin.
Topics: Acitretin; Humans; Keratolytic Agents; Male; Middle Aged; Nail Diseases; Psoriasis | 2009 |
Acitretin narrow-band TL-01 phototherapy but not etanercept treatment improves a localized inflammatory linear verrucous epidermal naevus with concomitant psoriasis.
Topics: Acitretin; Adult; Combined Modality Therapy; Etanercept; Humans; Immunoglobulin G; Male; Nevus; Phototherapy; Psoriasis; Receptors, Tumor Necrosis Factor | 2009 |
Palmoplantar pustulosis with arthro-osteitis: successful treatment with etanercept and acitretin.
Topics: Acitretin; Adult; Arthritis; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Keratolytic Agents; Male; Osteitis; Psoriasis; Receptors, Tumor Necrosis Factor; Treatment Outcome | 2009 |
Retinoids and phototherapy for psoriasis.
Topics: Acitretin; Combined Modality Therapy; Humans; Keratolytic Agents; Phototherapy; Psoriasis | 2009 |
[Psoriasis of von Zumbusch.
Topics: Acitretin; Adult; Humans; Keratolytic Agents; Male; Psoriasis; Treatment Outcome | 2009 |
Pregnancy outcome of women transfused during pregnancy with blood products inadvertently obtained from donors treated with acitretin.
Topics: Acitretin; Adult; Biological Products; Case-Control Studies; Drug Contamination; Female; Gestational Age; Half-Life; Humans; Infant, Newborn; Keratolytic Agents; Pregnancy; Pregnancy Outcome; Psoriasis; Teratogens; Transfusion Reaction | 2009 |
Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case.
Topics: Acitretin; Adult; Antibodies, Monoclonal, Humanized; Certolizumab Pegol; Colitis; Crohn Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Polyethylene Glycols; Psoriasis; Risk Assessment; Severity of Illness Index | 2009 |
Childhood psoriasis: often favorable outcome.
Topics: Acitretin; Administration, Topical; Anthralin; Calcitriol; Child; Cyclosporine; Dermatologic Agents; Emollients; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Methotrexate; Nicotinic Acids; Plant Extracts; Psoriasis; Receptors, Tumor Necrosis Factor; Salicylates; Steroids; Tars; Treatment Outcome; Ultraviolet Therapy | 2009 |
A dramatic response to a single dose of infliximab as rescue therapy in acute generalized pustular psoriasis of von Zumbusch associated with a neutrophilic cholangitis.
Topics: Acitretin; Antibodies, Monoclonal; Asian People; Cholangitis; Dermatologic Agents; Female; Humans; Infliximab; Liver Function Tests; Middle Aged; Neutrophil Infiltration; Psoriasis; Treatment Outcome; Tumor Necrosis Factor-alpha | 2010 |
Acute respiratory distress syndrome complicating generalized pustular psoriasis (psoriasis-associated aseptic pneumonitis).
Topics: Acitretin; Adolescent; Disease Progression; Female; Glucocorticoids; Heart Arrest; Humans; Keratolytic Agents; Leukocytosis; Pneumonia; Psoriasis; Respiratory Distress Syndrome; Tomography, X-Ray Computed | 2011 |
Treatment of psoriasis in patients with hepatitis C virus infection.
Topics: Acitretin; Antiviral Agents; Cyclosporine; Drug Eruptions; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Methotrexate; Psoriasis; Ribavirin | 2011 |
[Narrowband UV-B, monochromatic excimer laser, and photodynamic therapy in psoriasis: a consensus statement of the Spanish Psoriasis Group].
Topics: Acitretin; Adrenal Cortex Hormones; Adult; Child; Clinical Trials as Topic; Combined Modality Therapy; Comorbidity; Contraindications; Erythema; Female; Humans; Lasers, Excimer; Low-Level Light Therapy; Neoplasms, Radiation-Induced; Photochemotherapy; Pregnancy; Pregnancy Complications; Psoriasis; PUVA Therapy; Radiotherapy Dosage; Ultraviolet Therapy | 2011 |
Introducing the delayed retinoid burn: a case report and discussion of this potential risk of retinoid-phototherapy combination management.
Topics: Acitretin; Combined Modality Therapy; Dermatitis, Phototoxic; Female; Humans; Keratolytic Agents; Middle Aged; Psoriasis; Retinoids; Time Factors; Ultraviolet Therapy | 2011 |
Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
Topics: Acitretin; Adalimumab; Adrenal Cortex Hormones; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Calcitriol; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Methotrexate; Psoriasis; Receptors, Tumor Necrosis Factor; Tacrolimus; Treatment Outcome; Ustekinumab | 2011 |
[Oral acitretin and topical imiquimod as neoadjuvant treatment for giant basal cell carcinoma].
Topics: Acitretin; Administration, Cutaneous; Administration, Oral; Aged; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Basal Cell; Combined Modality Therapy; Facial Neoplasms; Female; Humans; Imiquimod; Neoadjuvant Therapy; Psoriasis; Remission Induction; Skin Neoplasms; Skin Ulcer; Thoracic Neoplasms | 2012 |
[News on psoriasis from the 2010 Dermatology Days in Paris].
Topics: Acitretin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Cyclosporine; Dermatologic Agents; Dermatology; Drug Therapy, Combination; Etanercept; Evidence-Based Medicine; Humans; Immunoglobulin G; Methotrexate; Practice Guidelines as Topic; Psoriasis; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor; Treatment Outcome; Ustekinumab | 2011 |
Superimposed linear psoriasis: low effectiveness of biologic therapy.
Topics: Acitretin; Aged; Antirheumatic Agents; Arthritis, Psoriatic; Biological Therapy; Cyclosporine; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Loss of Heterozygosity; Male; Methotrexate; Psoriasis; Receptors, Tumor Necrosis Factor | 2011 |
[Multiple warts appearing exclusively on psoriasis plaques].
Topics: Acitretin; Adrenal Cortex Hormones; Alphapapillomavirus; Human papillomavirus 6; Humans; Immunoglobulin A; Immunosuppressive Agents; Keratolytic Agents; Male; Methotrexate; Middle Aged; Papillomavirus Infections; Paraproteinemias; Psoriasis; Remission Induction; Ultraviolet Therapy; Warts | 2011 |
Acitretin for the treatment of psoriasis: an assessment of national trends.
Topics: Acitretin; Administration, Topical; Combined Modality Therapy; Databases, Factual; Dermatologic Agents; Disease Progression; Drug Therapy, Combination; Drug Utilization; Female; Humans; Keratolytic Agents; Male; Psoriasis; Retinoids; United States | 2011 |
Acitretin-induced retinoic acid syndrome.
Topics: Acitretin; Dermatologic Agents; Diagnosis, Differential; Fever; Humans; Hypotension; Lung Diseases, Interstitial; Male; Pericardial Effusion; Pleural Effusion; Pneumonia, Bacterial; Psoriasis; Respiratory Distress Syndrome; Syndrome; Tachycardia; Young Adult | 2011 |
[Acitretin].
Topics: Acitretin; Dermatologic Agents; Drug Monitoring; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Keratolytic Agents; Psoriasis | 2011 |
[Extensive Dowling-Degos disease following long term PUVA therapy].
Topics: Acitretin; Genes, Dominant; Humans; Keratin-5; Melanosis; Melanosomes; Middle Aged; Penetrance; Psoriasis; PUVA Therapy; Ultraviolet Rays | 2012 |
Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
Topics: Acitretin; Adalimumab; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Male; Melanoma; Methotrexate; Psoriasis; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Skin Neoplasms; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of hallopeau responsive to the interleukin 1 receptor antagonist anakinra.
Topics: Acitretin; Acrodermatitis; Antirheumatic Agents; Drug Administration Schedule; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypertriglyceridemia; Injections, Subcutaneous; Interleukin 1 Receptor Antagonist Protein; Keratolytic Agents; Middle Aged; Psoriasis; Receptors, Interleukin-1; Recombinant Proteins; Recurrence; Triglycerides; Tumor Necrosis Factor-alpha | 2012 |
Combination treatment with a tumour necrosis factor antagonist and an oral retinoid: efficacy in severe acral psoriasis?
Topics: Acitretin; Adolescent; Alitretinoin; Antibodies, Monoclonal; Dermatologic Agents; Drug Therapy, Combination; Humans; Infliximab; Male; Psoriasis; Severity of Illness Index; Treatment Outcome; Tretinoin; Tumor Necrosis Factor-alpha | 2012 |
Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris.
Topics: Acitretin; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; CD8-Positive T-Lymphocytes; Dermatitis, Atopic; Down-Regulation; Drug Administration Schedule; Etanercept; Female; Humans; Immunoglobulin G; Interleukin-10; Interleukin-17; Keratolytic Agents; Lymphocyte Count; Male; Middle Aged; Psoriasis; Receptors, Tumor Necrosis Factor; Signal Transduction; Skin; Th1 Cells; Th17 Cells; Th2 Cells; Treatment Outcome | 2012 |
Multiple eruptive squamous cell carcinoma in a patient with chronic plaque psoriasis on adalimumab.
Topics: Acitretin; Adalimumab; Aged; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Psoriasis; Skin Neoplasms | 2013 |
Refractory generalized pustular psoriasis responsive to a combination of adalimumab and acitretin.
Topics: Acitretin; Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Drug Therapy, Combination; Female; Humans; Keratolytic Agents; Psoriasis; Treatment Outcome; Young Adult | 2013 |
Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.
Topics: Acitretin; Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Cross-Sectional Studies; Etanercept; Female; Humans; Immunoglobulin G; Immunosuppressive Agents; Keratolytic Agents; Logistic Models; Male; Methotrexate; Middle Aged; Patient Satisfaction; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Surveys and Questionnaires; Treatment Outcome | 2013 |
Acitretin exerted a greater influence on T-helper (Th)1 and Th17 than on Th2 cells in treatment of psoriasis vulgaris.
Topics: Acitretin; Adolescent; Adult; Case-Control Studies; Female; Humans; Interferon-gamma; Interleukin-17; Interleukin-4; Keratolytic Agents; Male; Middle Aged; Psoriasis; RNA, Messenger; T-Lymphocyte Subsets; Th1 Cells; Th17 Cells; Th2 Cells; Young Adult | 2012 |
Combination of adalimumab with traditional systemic antipsoriatic drugs - a report of 39 cases.
Topics: Acitretin; Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; Treatment Outcome; Young Adult | 2012 |
Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how.
Topics: Acitretin; Basal Cell Nevus Syndrome; Dermatologic Agents; Humans; Isotretinoin; Off-Label Use; Organ Transplantation; Psoriasis; Risk Factors; Skin Neoplasms; Sunlight; Xeroderma Pigmentosum | 2013 |
Pseudoainhum in acute psoriasis.
Topics: Acitretin; Acute Disease; Aged; Ainhum; Anti-Inflammatory Agents; Biopsy; Clobetasol; Constriction, Pathologic; Female; Fingers; Humans; Keratolytic Agents; Male; Psoriasis; Treatment Outcome | 2012 |
Acitretin-induced transverse leukonychia.
Topics: Acitretin; Female; Humans; Keratolytic Agents; Middle Aged; Nail Diseases; Nails; Psoriasis | 2014 |
Respiratory distress with acitretin, reversal by corticosteroid.
Topics: Acitretin; Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Clarithromycin; Diagnosis, Differential; Humans; Infusions, Intravenous; Keratolytic Agents; Male; Pneumonia, Mycoplasma; Psoriasis; Respiratory Distress Syndrome | 2001 |
Rapid improvement of chronic interstitial keratitis with acitretin.
Topics: Acitretin; Adult; Chronic Disease; Humans; Keratitis; Keratolytic Agents; Male; Psoriasis; Tuberculosis | 2002 |
A case of bullous pemphigoid limited to psoriatic plaques.
Topics: Acitretin; Humans; Keratolytic Agents; Male; Middle Aged; Pemphigoid, Bullous; Psoriasis | 2002 |
Multiple cutaneous squamous carcinoma in a psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin.
Topics: Acitretin; Alcoholism; Carcinoma, Squamous Cell; Cyclosporine; Humans; Immunosuppressive Agents; Keratolytic Agents; Leg; Male; Middle Aged; Psoriasis; PUVA Therapy; Skin Neoplasms; Ultraviolet Rays | 2003 |
Tanning salons for psoriasis?
Topics: Acitretin; Humans; Keratolytic Agents; Psoriasis; Ultraviolet Therapy | 2003 |
Erythema gyratum repens in a case of resolving psoriasis.
Topics: Acitretin; Erythema; Humans; Male; Middle Aged; Psoriasis | 2003 |
Retrospective study of the efficacy of narrowband UVB and acitretin.
Topics: Acitretin; Humans; Keratolytic Agents; Psoriasis; Retrospective Studies; Treatment Outcome; Ultraviolet Therapy | 2003 |
Case studies in severe psoriasis: A clinical strategy.
Topics: Acitretin; Adolescent; Adult; Aged; Algorithms; Dermatologic Agents; Drug Therapy, Combination; Etretinate; Female; Health Surveys; Humans; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; Recombinant Fusion Proteins; Severity of Illness Index; Treatment Outcome; Ultraviolet Therapy | 2003 |
Keratoderma blennorrhagicum.
Topics: Acitretin; Adult; HIV Infections; Humans; Keratolytic Agents; Keratosis; Male; Psoriasis | 2003 |
Biologics for psoriasis.
Topics: Acitretin; Biological Products; Humans; Keratolytic Agents; Prevalence; Psoriasis; Quality of Life; Severity of Illness Index; United States | 2003 |
Capillary leak syndrome induced by acitretin.
Topics: Acitretin; Aged; Capillary Leak Syndrome; Humans; Keratolytic Agents; Male; Psoriasis | 2004 |
Single-center retrospective study of long-term use of low-dose acitretin (Soriatane) for psoriasis.
Topics: Acitretin; Adolescent; Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis; Retrospective Studies; Time Factors | 2004 |
An impressive therapeutic result of nail psoriasis to acitretin.
Topics: Acitretin; Adult; Humans; Keratolytic Agents; Male; Nail Diseases; Psoriasis | 2004 |
[Patient memo. Advice for patients with psoriasis and using Soriatane].
Topics: Abnormalities, Drug-Induced; Acitretin; Adult; Cholesterol; Dose-Response Relationship, Drug; Female; Humans; Keratolytic Agents; Liver; Male; Monitoring, Physiologic; Pregnancy; Psoriasis; Triglycerides | 2004 |
Acitretin-associated maculopathy.
Topics: Acetazolamide; Acitretin; Adult; Diuretics; Fluorescein Angiography; Humans; Keratolytic Agents; Macular Edema; Male; Psoriasis; Retina; Retinal Diseases; Visual Acuity | 2004 |
Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type.
Topics: Acitretin; Child, Preschool; Combined Modality Therapy; Humans; Keratolytic Agents; Male; Psoriasis; Ultraviolet Therapy | 2004 |
Sequential therapy using cyclosporine and acitretin for treatment of total body psoriasis.
Topics: Acitretin; Administration, Cutaneous; Adult; Cyclosporine; Dermatologic Agents; Humans; Keratolytic Agents; Male; Psoriasis; Skin; Treatment Outcome | 2004 |
Systemic therapy does not usually clear psoriasis, but treatment success does not require clearing.
Topics: Acitretin; Cyclosporine; Female; Ficusin; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Methotrexate; Middle Aged; Patient Satisfaction; Photosensitizing Agents; Psoriasis; PUVA Therapy; Treatment Outcome | 2005 |
Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey.
Topics: Acitretin; Adult; Aged; Cyclosporine; Dermatologic Agents; Female; Ficusin; Health Surveys; Humans; Male; Methotrexate; Middle Aged; Patient Satisfaction; Psoriasis; PUVA Therapy; Treatment Outcome; United States | 2005 |
Re-climatotherapy: a combination of acitretin and climatotherapy at the Dead Sea.
Topics: Acitretin; Adult; Balneology; Combined Modality Therapy; Female; Heliotherapy; Humans; Israel; Keratolytic Agents; Male; Middle Aged; Oceans and Seas; Psoriasis; Seawater | 2005 |
Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
Topics: Acitretin; Adult; Costs and Cost Analysis; Cyclosporine; Dermatologic Agents; Female; Health Care Costs; Humans; Male; Managed Care Programs; Methotrexate; Middle Aged; New England; Phototherapy; Psoriasis; PUVA Therapy; Treatment Failure; United States | 2005 |
Modern modified 'ultra' Goeckerman therapy: a PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies.
Topics: Acitretin; Anthralin; Calcitriol; Coal Tar; Combined Modality Therapy; Female; Humans; Keratolytic Agents; Male; Methotrexate; Middle Aged; Nicotinic Acids; Phototherapy; Psoriasis; Salicylic Acid; Severity of Illness Index; Time Factors; Ultraviolet Therapy | 2005 |
Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines.
Topics: Acitretin; Adiponectin; Adult; Blood Glucose; Cholesterol, HDL; Cohort Studies; Humans; Insulin Resistance; Lipids; Male; Middle Aged; Prospective Studies; Psoriasis; Resistin | 2006 |
Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis.
Topics: Acitretin; Cells, Cultured; Female; Gene Expression Regulation; Genotype; Humans; Keratinocytes; Leukocytes, Mononuclear; Male; Polymorphism, Genetic; Psoriasis; Retinoids; Tretinoin; Vascular Endothelial Growth Factor A | 2006 |
Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin.
Topics: Acitretin; Adolescent; Adult; Aged; Aged, 80 and over; Apolipoprotein E4; Apolipoproteins E; Child; Female; Genetic Markers; Genetic Predisposition to Disease; Genotype; Humans; Hypertriglyceridemia; Keratolytic Agents; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Psoriasis; Sequence Analysis, DNA; Treatment Outcome | 2006 |
Effects of chronic retinoid administration on pituitary function.
Topics: Acitretin; Adult; Follicle Stimulating Hormone; Humans; Hydrocortisone; Insulin-Like Growth Factor I; Keratolytic Agents; Luteinizing Hormone; Male; Pituitary Gland; Prolactin; Psoriasis; Testosterone; Thyrotropin; Thyrotropin-Releasing Hormone; Thyroxine; Triiodothyronine | 2005 |
Occupational trachyonychia due to psoriasis: report of a case successfully treated with oral acitretin.
Topics: Acitretin; Administration, Oral; Adult; Dermatitis, Occupational; Diagnosis, Differential; Humans; Keratolytic Agents; Male; Nail Diseases; Psoriasis | 2006 |
Increased suicidal tendency in a case of psoriasis vulgaris under acitretin treatment.
Topics: Acitretin; Adult; Female; Humans; Keratolytic Agents; Psoriasis; Suicide | 2006 |
Acitretin induced bipedal edema.
Topics: Acitretin; Diagnosis, Differential; Edema; Foot Diseases; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis | 2006 |
Novel combination regimens: biologics and acitretin for the treatment of psoriasis-- a case series.
Topics: Acitretin; Administration, Oral; Adolescent; Adult; Aged; Drug Administration Schedule; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Immunologic Factors; Keratolytic Agents; Male; Middle Aged; Psoriasis; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Severity of Illness Index | 2006 |
Combination therapy with acitretin for psoriasis.
Topics: Acitretin; Adult; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Keratolytic Agents; Male; Methotrexate; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Severity of Illness Index | 2006 |
A woman with sudden bilateral sensorineural hearing loss after treatment psoriasis with acitretin.
Topics: Acitretin; Adult; Female; Hearing Loss, Bilateral; Hearing Loss, Sensorineural; Humans; Keratolytic Agents; Psoriasis | 2005 |
[The burned man].
Topics: Acitretin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Inflammatory Agents; Drug Therapy, Combination; Histamine H1 Antagonists; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis | 2006 |
The effect of various methods of psoriasis treatment on somatotrophin axis hormones in serum.
Topics: Acitretin; Adult; Case-Control Studies; Female; Growth Hormone; Humans; Hydroxyurea; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Keratolytic Agents; Male; Phototherapy; Psoriasis; Severity of Illness Index | 2006 |
Acitretin-induced erythroderma in a psoriatic patient.
Topics: Acitretin; Adult; Dermatitis, Exfoliative; Humans; Keratolytic Agents; Male; Psoriasis | 2006 |
Etanercept and recalcitrant acrodermatitis continua of Hallopeau.
Topics: Acitretin; Acrodermatitis; Aged; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G; Keratolytic Agents; Psoriasis; Receptors, Tumor Necrosis Factor | 2006 |
Acitretin induces capillary leak syndrome in a patient with pustular psoriasis.
Topics: Acitretin; Aged; Capillary Leak Syndrome; Dyspnea; Edema; Female; Humans; Keratolytic Agents; Psoriasis | 2007 |
Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions.
Topics: Acitretin; Administration, Oral; Adult; Cyclosporine; Dermatologic Agents; Female; Humans; Keratolytic Agents; Male; Methotrexate; Patient Satisfaction; Psoriasis; PUVA Therapy; Surveys and Questionnaires; Treatment Outcome; Ultraviolet Therapy | 2007 |
Effects of topically applied acitretin in reconstructed human epidermis and the rhino mouse.
Topics: Acitretin; Administration, Topical; Animals; Disease Models, Animal; Epidermis; Female; Filaggrin Proteins; Humans; Interleukin-1alpha; Interleukin-8; Keratin-10; Keratin-19; Keratolytic Agents; Male; Mice; Mice, Hairless; Nicotinic Acids; Psoriasis; Tretinoin | 2008 |
Case of multiple verrucous carcinomas responding to treatment with acetretin more likely to have been a case of verrucous psoriasis.
Topics: Acitretin; Carcinoma, Verrucous; Diagnosis, Differential; Humans; Keratolytic Agents; Neoplasms, Second Primary; Psoriasis; Skin Neoplasms; Treatment Outcome; Warts | 2007 |
The efficacy of combination treatment with narrowband UVB (TL-01) and acitretin vs narrowband UVB alone in plaque-type psoriasis: a retrospective study.
Topics: Acitretin; Adolescent; Adult; Aged; Chi-Square Distribution; Combined Modality Therapy; Female; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis; Treatment Outcome; Ultraviolet Therapy | 2006 |
Conventional therapies for psoriasis.
Topics: Acitretin; Cyclosporine; Dermatologic Agents; Drug Therapy, Combination; Humans; Italy; Keratolytic Agents; Methotrexate; Psoriasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
Acquired kinking of the hair caused by acitretin.
Topics: Acitretin; Dose-Response Relationship, Drug; Female; Hair; Hair Diseases; Humans; Keratolytic Agents; Middle Aged; Psoriasis; Time Factors | 2007 |
Granulation tissue in palpebral conjunctivae associated with acitretin therapy.
Topics: Acitretin; Adult; Conjunctiva; Granulation Tissue; Humans; Male; Psoriasis | 2008 |
Combination of efalizumab and acitretin in chronic plaque psoriasis.
Topics: Acitretin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Chronic Disease; Drug Therapy, Combination; Female; Humans; Keratolytic Agents; Middle Aged; Psoriasis; Skin | 2008 |
[Management of severe psoriasis: about 50 cases].
Topics: Acitretin; Adolescent; Adult; Aged; Arthritis, Psoriatic; Child; Dermatitis, Exfoliative; Female; Follow-Up Studies; Humans; Keratolytic Agents; Male; Methotrexate; Middle Aged; Psoriasis; PUVA Therapy; Quality of Life; Retinoids; Retrospective Studies; Treatment Outcome | 2007 |
Generalized pustular psoriasis and cryptogenic organizing pneumonia.
Topics: Acitretin; Adult; Arthritis, Psoriatic; Cryptogenic Organizing Pneumonia; Cyclosporine; Dermatologic Agents; Etanercept; Fatal Outcome; Female; Humans; Immunoglobulin G; Protein C Inhibitor; Psoriasis; Receptors, Tumor Necrosis Factor | 2008 |
Concurrent use of methotrexate and acitretin revisited.
Topics: Acitretin; Adolescent; Adult; Aged; Alcohol Drinking; Alopecia; Chemical and Drug Induced Liver Injury; Child; Contraindications; Dermatologic Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Liver Function Tests; Male; Methotrexate; Middle Aged; Psoriasis; Retrospective Studies; Treatment Outcome | 2008 |
[Acitretin-induced pneumonia: an underestimated complication of treatment of psoriasis].
Topics: Acitretin; Adrenal Cortex Hormones; Aged, 80 and over; Female; Humans; Keratolytic Agents; Pneumonia; Psoriasis; Radiography, Thoracic | 2008 |
Combining systemic retinoids with biologic agents for moderate to severe psoriasis.
Topics: Acitretin; Adalimumab; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Female; Humans; Immunoglobulin G; Immunologic Factors; Infliximab; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Squamous Cell; Psoriasis; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Retrospective Studies; Serum Sickness; Skin Neoplasms; Treatment Outcome | 2008 |
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Topics: Acitretin; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Biological Products; Cardiovascular Diseases; Cyclosporine; Depression; Etanercept; Humans; Immunoglobulin G; Interleukin-12; Interleukin-23; Lymphoma; Metabolic Syndrome; Methotrexate; Obesity; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Smoking; Tumor Necrosis Factor-alpha | 2008 |
Erythroderma in a patient taking acitretin for plaque psoriasis.
Topics: Acitretin; Cyclosporine; Dermatitis, Exfoliative; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis | 2008 |
Plasma and suction blister fluid levels of etretinate and its main metabolite during treatment of psoriasis.
Topics: Acitretin; Adult; Biological Availability; Blister; Etretinate; Exudates and Transudates; Female; Half-Life; Humans; Male; Middle Aged; Psoriasis; Time Factors; Tretinoin | 1982 |
Serum levels of Etretinate (Ro 10-9359) and its metabolite (Ro 10-1670).
Topics: Acitretin; Adolescent; Adult; Etretinate; Female; Humans; Keratoderma, Palmoplantar; Male; Middle Aged; Pityriasis; Psoriasis; Tretinoin | 1983 |
Pharmacokinetics of acitretin.
Topics: Acitretin; Adult; Aged; Female; Humans; Male; Middle Aged; Psoriasis | 1994 |
Serum levels of interferons and TNF-alpha are not correlated to psoriasis activity and therapy.
Topics: Acitretin; Adult; Aged; Aged, 80 and over; Coal Tar; Cyclosporine; Humans; Interferon Type I; Interferon-alpha; Middle Aged; Pregnancy Proteins; Psoriasis; Tumor Necrosis Factor-alpha; Ultraviolet Therapy | 1994 |
Skin, adipose tissue and plasma levels of acitretin with rare occurrence of esterified acitretin during long-term treatment.
Topics: Acitretin; Adipose Tissue; Adult; Aged; Chromatography, High Pressure Liquid; Esterification; Etretinate; Female; Humans; Keratosis; Male; Middle Aged; Psoriasis; Skin; Time Factors | 1993 |
Acitretin does not prevent psoriasis relapse related to cyclosporin A tapering.
Topics: Acitretin; Chronic Disease; Cyclosporine; Female; Humans; Male; Middle Aged; Pilot Projects; Psoriasis; Recurrence; Remission Induction | 1994 |
The effects of retinoids and terbinafine on the human hepatic microsomal metabolism of cyclosporin.
Topics: Acitretin; Aged; Antifungal Agents; Cyclosporine; Drug Therapy, Combination; Etretinate; Female; Humans; In Vitro Techniques; Isotretinoin; Male; Microsomes, Liver; Middle Aged; Naphthalenes; Psoriasis; Retinoids; Terbinafine | 1993 |
[Acute hepatic involvement during ingestion of acitretin].
Topics: Acitretin; Acute Disease; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Humans; Male; Psoriasis | 1993 |
[Distribution of acitretin in human skin].
Topics: Acitretin; Administration, Oral; Administration, Topical; Adult; Biopsy; Chromatography, High Pressure Liquid; Humans; Male; Psoriasis; Skin | 1993 |
Psoriasis and birdshot chorioretinopathy: response to aromatic retinoids.
Topics: Acitretin; Chorioretinitis; Drug Therapy, Combination; Etretinate; Humans; Male; Middle Aged; Psoriasis; Vitiligo | 1993 |
Rapid effect of treatment of psoriatic erythrocytes with the synthetic retinoid acitretin to increase 8-azido cyclic AMP binding to the RI regulatory subunit.
Topics: Acitretin; Affinity Labels; Azides; Cell Separation; Cyclic AMP; Dose-Response Relationship, Drug; Erythrocyte Membrane; Erythrocytes; Humans; Protein Kinases; Psoriasis; Time Factors | 1993 |
Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol.
Topics: Acitretin; Adult; Alcohol Drinking; Ethanol; Etretinate; Female; Half-Life; Humans; Male; Middle Aged; Osmolar Concentration; Psoriasis; Time Factors | 1993 |
Pseudoallergic hepatitis after a single intake of 10 mg acitretin (Neotigason) for treatment of psoriasis pustulosa.
Topics: Acitretin; Adult; Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Female; Humans; Keratolytic Agents; Psoriasis | 1995 |
Response of the clinically uninvolved skin of psoriatic patients to tape stripping during acitretin treatment.
Topics: Acitretin; Adult; Aged; Antibodies, Monoclonal; Bandages; Biopsy; Cell Division; Filaggrin Proteins; Humans; Immunohistochemistry; Intermediate Filament Proteins; Keratolytic Agents; Ki-67 Antigen; Middle Aged; Neoplasm Proteins; Nuclear Proteins; Protein Precursors; Psoriasis; Skin; T-Lymphocytes | 1996 |
Acrodermatitis continua of Hallopeau in a patient with myelodysplastic syndrome.
Topics: Acitretin; Acrodermatitis; Acute Disease; Cell Transformation, Neoplastic; Contraindications; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Psoriasis | 1996 |
Multiple dermatofibromas in a patient with HIV infection.
Topics: Acitretin; Adult; Hemophilia B; Histiocytoma, Benign Fibrous; HIV Infections; Humans; Male; Prednisolone; Psoriasis; Skin Neoplasms; Ultraviolet Therapy | 1995 |
Plasma endothelin in psoriasis: possible relations to therapy and toxicity.
Topics: Acitretin; Cyclosporine; Endothelins; Humans; Hydroxyurea; Keratolytic Agents; Methotrexate; Psoriasis; Ranitidine | 1996 |
Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance.
Topics: Acitretin; Carcinoma, Squamous Cell; Cyclosporine; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Middle Aged; Neoplasms, Multiple Primary; Psoriasis; PUVA Therapy; Skin Neoplasms | 1997 |
Etretinate may work where acitretin fails.
Topics: Acitretin; Adolescent; Adult; Aged; Aged, 80 and over; Darier Disease; Etretinate; Female; Hand Dermatoses; Humans; Keratoderma, Palmoplantar; Keratolytic Agents; Male; Psoriasis; Skin Diseases; Treatment Failure | 1997 |
The combination of oral acitretin and bath PUVA for the treatment of severe psoriasis.
Topics: Acitretin; Adult; Aged; Drug Therapy, Combination; Follow-Up Studies; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis; PUVA Therapy | 1997 |
Two new retinoids for psoriasis.
Topics: Abnormalities, Drug-Induced; Acitretin; Alopecia; Cheilitis; Clinical Trials as Topic; Dermatologic Agents; Drug Costs; Drug Interactions; Feces; Gels; Humans; Keratolytic Agents; Nicotinic Acids; Psoriasis | 1997 |
Juvenile generalized pustular psoriasis.
Topics: Acitretin; Child; Humans; Keratolytic Agents; Male; Psoriasis | 1998 |
Comparison of actual psoriasis surface area and the psoriasis area and severity index by the human eye and machine vision methods in following the treatment of psoriasis.
Topics: Acitretin; Administration, Topical; Adult; Aged; Anthralin; Anti-Inflammatory Agents; Calcitriol; Color; Dermatologic Agents; Eye; Female; Humans; Image Processing, Computer-Assisted; Keratolytic Agents; Male; Middle Aged; Photography; Psoriasis; PUVA Therapy; Quality Control; Reproducibility of Results; Severity of Illness Index; Skin; Tars | 1998 |
Cyclosporine treatment of psoriatic erythroderma complicated by bacterial sepsis.
Topics: Acitretin; Anti-Bacterial Agents; Cefazolin; Cephalosporins; Cyclosporine; Dermatitis, Exfoliative; Dermatologic Agents; Humans; Immunosuppressive Agents; Keratolytic Agents; Male; Middle Aged; Psoriasis; Sepsis; Staphylococcal Infections; Streptococcal Infections; Vancomycin | 1999 |
Coexistence of morphea and psoriasis responding to acitretin treatment.
Topics: Acitretin; Collagen; Female; Humans; Keratolytic Agents; Middle Aged; Psoriasis; Scleroderma, Localized; Skin | 1999 |
Psoriasis associated with HCV and exacerbated by interferon alpha: complete clearance with acitretin during interferon alpha treatment for chronic active hepatitis.
Topics: Acitretin; Aged; Antiviral Agents; Hepacivirus; Hepatitis, Chronic; Humans; Interferon-alpha; Keratolytic Agents; Male; Psoriasis | 2000 |
Acitretin therapy for palmoplantar pustulosis combined with UVA and topical 8-MOP.
Topics: Acitretin; Administration, Topical; Adult; Combined Modality Therapy; Female; Humans; Keratolytic Agents; Male; Methoxsalen; Middle Aged; Psoriasis; PUVA Therapy | 2001 |
Severe cholestatic hepatitis in a patient taking acitretin.
Topics: Acitretin; Chemical and Drug Induced Liver Injury; Cholestasis; Humans; Keratolytic Agents; Male; Middle Aged; Psoriasis | 2002 |
Oral acitretin in psoriasis: drug and vitamin A concentrations in plasma, skin and adipose tissue.
Topics: Acitretin; Adipose Tissue; Administration, Oral; Adult; Female; Humans; Male; Middle Aged; Psoriasis; Skin; Tretinoin; Vitamin A | 1992 |
Efficacy and skeletal side effects of two years' acitretin treatment.
Topics: Acitretin; Adolescent; Adult; Aged; Bone Diseases; Calcinosis; Female; Follow-Up Studies; Humans; Ichthyosis; Male; Middle Aged; Prospective Studies; Psoriasis; Radiography; Remission Induction | 1992 |
Cytokine-stimulated human dermal microvascular endothelial cells produce interleukin 6--inhibition by hydrocortisone, dexamethasone, and calcitriol.
Topics: Acitretin; Calcitriol; Cyclosporine; Cytokines; Dexamethasone; Drug Therapy, Combination; Endothelium, Vascular; Humans; Hydrocortisone; Infant; Infant, Newborn; Interleukin-1; Interleukin-6; Male; Microcirculation; Psoriasis; Skin; Tumor Necrosis Factor-alpha | 1992 |
Psoriasis symposum. Retinoids.
Topics: Acitretin; Etretinate; Humans; Psoriasis; Retinoids | 1992 |
The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients.
Topics: Acitretin; Adult; Blister; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Psoriasis; Saliva; Tretinoin | 1991 |
Acitretin excretion into human breast milk.
Topics: Acitretin; Adult; Chromatography, High Pressure Liquid; Female; Humans; Milk, Human; Psoriasis; Tretinoin | 1990 |
[Pharmacokinetics of etretinate, acitretin and 13-cis-acitretin: new results and advantages of blood level oriented clinical use].
Topics: Acitretin; Administration, Oral; Adult; Aged; Chromatography, High Pressure Liquid; Etretinate; Female; Humans; Long-Term Care; Male; Middle Aged; Psoriasis; Skin Diseases; Tretinoin | 1990 |
Etretin. A replacement for etretinate.
Topics: Acitretin; Etretinate; Humans; Psoriasis; Tretinoin | 1990 |
Synthesis and characterization of new 10-acylderivatives of the antipsoriatic agent dithranol: coupling products of dithranol with all-trans-retinoic acid, 13-cis-retinoid acid and an aromatic analogue of retinoic acid: all-trans-9-(4-methoxy-2,3,6-trimet
Topics: Acitretin; Anthralin; Isotretinoin; Magnetic Resonance Spectroscopy; Psoriasis; Tretinoin | 1990 |
Therapy with a synthetic retinoid--(Ro 10-1670) etretin--increases the cellular retinoic acid-binding protein in nonlesional psoriatic skin.
Topics: Acitretin; Adult; Aged; Carrier Proteins; Charcoal; Chromatography, Gel; Dextrans; Female; Humans; Male; Middle Aged; Psoriasis; Receptors, Retinoic Acid; Retinol-Binding Proteins; Retinol-Binding Proteins, Cellular; Skin; Tretinoin | 1986 |
Skin cellular retinoid-binding proteins and retinoid-responsive dermatoses.
Topics: Acitretin; Adsorption; Carrier Proteins; Charcoal; Chromatography, Gel; Dextrans; Female; Humans; Male; Psoriasis; Receptors, Retinoic Acid; Retinol-Binding Proteins; Retinol-Binding Proteins, Cellular; Skin; Skin Diseases; Tretinoin | 1986 |
Tissue distribution of aromatic retinoid (etretinate) in three autopsy cases: drug accumulation in adrenals and fat.
Topics: Acitretin; Adipose Tissue; Adrenal Glands; Adult; Aged; Aged, 80 and over; Etretinate; Humans; Ichthyosis; Male; Psoriasis; Tissue Distribution; Tretinoin | 1986 |
The effect of the antipsoriatic drug metabolite etretin (Ro 10-1670) on UVB irradiation induced changes in the metabolism of arachidonic acid in human keratinocytes in culture.
Topics: Acitretin; Arachidonic Acid; Arachidonic Acids; Cell Line; Humans; Keratins; Psoriasis; Skin; Tretinoin; Ultraviolet Rays | 1986 |
Neutrophil function in psoriasis: effects of retinoids.
Topics: Acitretin; Dermatologic Agents; Etretinate; Female; Humans; In Vitro Techniques; Isotretinoin; Luminescent Measurements; Middle Aged; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Phagocytosis; Psoriasis; Retinoids; Tetradecanoylphorbol Acetate; Tretinoin | 1987 |
Serum lipid changes during acitretin (etretin) treatment of psoriasis and palmo-plantar pustulosis.
Topics: Acitretin; Adult; Apolipoproteins; Cholesterol; Fat Emulsions, Intravenous; Female; Foot Dermatoses; Hand Dermatoses; Humans; Lipids; Lipoproteins; Male; Middle Aged; Psoriasis; Skin Diseases, Vesiculobullous; Tretinoin | 1988 |
Acitretin treatment of severe psoriasis.
Topics: Acitretin; Adult; Humans; Male; Middle Aged; Psoriasis; Severity of Illness Index; Tretinoin | 1989 |
Pharmacokinetics of etretinate in psoriatic patients with liver fibrosis.
Topics: Acitretin; Aged; Etretinate; Female; Half-Life; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Psoriasis; Tretinoin | 1989 |
Determination of acitretin and 13-cis-acitretin in skin.
Topics: Acitretin; Administration, Oral; Adult; Aged; Animals; Chromatography, High Pressure Liquid; Humans; Male; Middle Aged; Psoriasis; Rats; Skin; Stereoisomerism; Tretinoin | 1989 |
Simultaneous determination of the aromatic retinoids etretin and etretinate and their main metabolites by reversed-phase liquid chromatography.
Topics: Acitretin; Chromatography, High Pressure Liquid; Etretinate; Humans; Isomerism; Kinetics; Psoriasis; Tretinoin | 1987 |
Etretinate pharmacokinetics in chronic renal failure. A preliminary study in psoriasis patients.
Topics: Acitretin; Etretinate; Humans; Kidney Failure, Chronic; Kidney Function Tests; Psoriasis; Tretinoin | 1987 |
Proliferation and glycosaminoglycans secretion in fibroblasts from psoriatic skin: differential responses to retinoids.
Topics: Acitretin; Cell Division; Cell Line; Fibroblasts; Glycosaminoglycans; Humans; Isotretinoin; Psoriasis; Retinoids; Skin; Tretinoin | 1987 |
Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients.
Topics: Acitretin; Adult; Aged; Etretinate; Female; Half-Life; Humans; Male; Middle Aged; Psoriasis; Tretinoin | 1988 |
Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies.
Topics: Acitretin; Adolescent; Adult; Child; Child, Preschool; Etretinate; Female; Humans; Male; Middle Aged; Psoriasis; Skin; Tretinoin | 1988 |
Fish oil supplementation results in decreased hypertriglyceridemia in patients with psoriasis undergoing etretinate or acitretin therapy.
Topics: Acitretin; Adult; Aged; Cholesterol; Cholesterol, HDL; Etretinate; Female; Fish Oils; Humans; Hyperlipoproteinemias; Male; Middle Aged; Prothrombin Time; Psoriasis; Tretinoin; Triglycerides | 1988 |
Effects of retinoids in bone.
Topics: Acitretin; Adult; Humans; Isotretinoin; Psoriasis; Spinal Diseases; Time Factors; Tretinoin | 1988 |
Residual plasma concentrations of acitretin (Ro 10-1670) and its metabolite (Ro 13-7652) after chronic administration.
Topics: Acitretin; Adolescent; Adult; Aged; Chromatography, High Pressure Liquid; Female; Humans; Lichen Planus; Male; Middle Aged; Psoriasis; Tretinoin | 1988 |
Cis-trans interconversion of acitretin in man.
Topics: Acitretin; Adult; Aged; Animals; Biotransformation; Dermatitis; Female; Half-Life; Humans; Male; Middle Aged; Psoriasis; Rats; Skin Diseases; Stereoisomerism; Tretinoin | 1988 |